study

Dean Baker: Economists Tell the Masses: "It Could Have Been Worse"

August 2, 2010

It is amazing that angry mobs have not risen up and chased all the economists out of the country. While the greed of the Wall Street gang provided the fuel for the bubble, the economists played an essential role as enablers. This was most directly true for economists in policymaking positions, like Alan Greenspan at the Fed. It was Greenspan’s job to stop the housing bubble. A competent and honest Fed chair would have recognized the bubble by 2002 and taken whatever steps were necessary to rein it in. And we should be 100 percent clear, in spite of all the song and dance about how the financial reform bill will prevent another bailout, the Fed absolutely had all the tools needed to stop this disaster. They just lacked either the competence or the integrity, or both. But the economists in policymaking positions are just the beginning. There are thousands of macroeconomists across the country, in government, academia and private industry who track the economy as a full-time job. It is actually a well-paid job, with many drawing six-figure salaries and big name types getting close to $1 million a year. Given the high pay for this profession, it was reasonable to expect that they would be able to see something like the $8 trillion housing bubble that eventually wrecked the economy when it collapsed. But you can count on your fingers the number of economists who raised warnings about the housing bubble. The rest either did not see it, or didn’t think it worth mentioning. Remarkably, no economists seem to have lost their jobs for this failing. Unlike dishwashers and custodians, economists are not held accountable for the quality of their work. Now, the economists are back telling us that we should be thankful that Congress and the Fed enacted the TARP and the other programs that saved Goldman Sachs, Citigroup, and the rest from bankruptcy. A new study by Princeton University Professor Alan Blinder and Mark Zandi, the chief economist at Moody’s Analytics, examined the impact of the TARP and the related Fed and FDIC bailout programs. The study found that without the bailout, GDP would have declined by another 6.5 percent and the economy would have lost another 8.5 million jobs. In other words, things might be bad now, but if we didn’t shovel trillions in loans and loan guarantees to Goldman Sachs and the rest of the Wall Street gang, they would be even worse. Before we start thanking Goldman for taking our money, it is worth taking a closer look at the study. The big story here is the counterfactual. What does the study assume the Fed and Treasury would have done if we had not passed the TARP and the Fed had not come through with its vast array of emergency loan and loan guarantee programs? The answer is that the study assumes that they would have done nothing. In other words, the question asked by the study is “what would the world look like if the federal government had done absolutely nothing to counter the economic and financial downturn resulting from collapse of the housing bubble?” This counterfactual seems more than a bit unrealistic. Suppose we had let the market work its magic and put Goldman, Citigroup, Bank of America, and Morgan Stanley into bankruptcy. Suppose that once these firms were in receivership and their bank units were in the hands of the FDIC, the Fed flooded the system with liquidity. How would this situation compare with the situation where trillions of taxpayer dollars were put at the discretion of Goldman and the rest through TARP and the Fed’s special facilities? The Blinder-Zandi study tells us absolutely nothing about this scenario. In other words, Blinder and Zandi have constructed an absurdly unrealistic counterfactual and told us that the TARP was much better than this absurd scenario. This is like saying that people who don’t eat chicken will starve to death. Under the counterfactual that people who don’t chicken don’t eat anything else either, they certainly will starve to death. But that is not a serious analysis of the benefits of eating chicken, and Blinder and Zandi have not given us a serious analysis of the benefits of the TARP. This “it could have been worse” line should be flushed down the toilet. The reality is that greed and incompetence created an entirely unnecessary disaster. Tens of millions of people are still suffering from its consequences. And the Wall Street boys and the economists who are responsible for the disaster are all doing just fine. People should be really angry about this and a silly study that might be used to tell them otherwise should just make them angrier.

Read the full article →

Dan Solin: Upton Sinclair’s Insight for Improving Your 401(k) Returns

July 27, 2010

It’s surprising that Upton Sinclair would provide today’s investors with an insight for investing success. He was born on September 20, 1878. His parents were very poor. His father was an alcoholic. His grandparents were quite wealthy. The stark difference in the financial circumstances of his parents and grandparents influenced him to become one of the most prominent socialists of his time. He even ran (without success) as the Socialist’s Party’s candidate for Congress from New Jersey. What can this avowed socialist teach us about investing? Here’s a quote attributed to him. It says it all: “It is difficult to get a man to understand something when his salary depends upon his not understanding it.” The salaries of brokers and insurance company representatives depend on persuading employers with 401(k) plans to include actively managed funds (where the fund manager attempts to beat a designated benchmark) as investment options in the plan. Billions in fees is generated in this way. The overwhelming evidence supports the view that most of this money is wasted. Plan participants would achieve significantly greater returns if no actively managed funds were in their plans. Instead,the plans should offer a limited number of pre-allocated, globally diversified portfolios of low cost index funds, Exchange Traded Funds or passively managed funds. People who make a living selling actively managed funds react to this news much like a speech by a vegetarian is received at a cattlemen’s convention. One reader (a broker) patiently explained that I didn’t understand the math. He believes the support for index funds in the press is caused by its willingness to accept glib statements from bloggers (like me). He provided no data to support his view. Two distinguished finance professors who clearly do “understand the math” are Eugene F. Fama, a Professor of Finance at the University of Chicago, Booth School of Business, and Kenneth F. French, a Professor of Finance at Dartmouth College, Tuck School of Business. In their recent study , Luck Versus Skill in the Cross Section of Mutual Fund Returns , they attribute outperformance of actively managed funds to luck and not skill. Because there is no evidence of skill, it’s not surprising those funds that do perform well over a given period of time typically cannot repeat their stellar performance. The ramifications of this study hit brokers and insurance companies right where it hurts — in their pockets. If employers understood this data, they would not include actively managed funds in their 401(k) plans because those funds are likely to underperform passive benchmarks by almost 1% per year. The reaction to studies of this sort is interesting. Another reader explained his strongly held view that “managed funds” should be in all 401(k) plans. He bragged his credentials included an M.B.A. He was a consultant to corporations and boards on how to reduce their fiduciary risk. I responded with a number of studies (including some by Nobel Prize winners in Economics) rebutting his views. I encouraged him to send me peer reviewed studies with contrary data. I told him I had an easy solution for eliminating fiduciary liability, rather than simply mitigating it: Require investment advisors to 401(k) plans to be 3(38) ERISA fiduciaries and to accept 100% of the liability for the selection and monitoring of plan assets. Here’s his response: He doesn’t believe in academic studies. He has no confidence in the committee that appoints Nobel Prize winners. He sent me no data. The pattern is very familiar. Research is responded to with rhetoric, but no contrary data. Unfortunately, their clients often don’t have the sophistication to confront them with studies that demonstrate what they are selling is in their best interest, but not in the best interest of the participants in the plan. Employers need to appreciate their potential exposure as fiduciaries to plan participants. It’s only a matter of time before an enlightened court reviews the studies and concludes the inclusion of any actively managed fund in a 401(k) plan violates the duty of prudence. Brokers and insurance companies will never “understand” this evidence. Their salaries depend on their not understanding it. The views set forth in this blog are the opinions of the author alone and may not represent the views of any firm or entity with whom he is affiliated. The data, information, and content on this blog are for information, education, and non-commercial purposes only. Returns from index funds do not represent the performance of any investment advisory firm. The information on this blog does not involve the rendering of personalized investment advice and is limited to the dissemination of opinions on investing. No reader should construe these opinions as an offer of advisory services. Readers who require investment advice should retain the services of a competent investment professional. The information on this blog is not an offer to buy or sell, or a solicitation of any offer to buy or sell any securities or class of securities mentioned herein. Furthermore, the information on this blog should not be construed as an offer of advisory services. Please note that the author does not recommend specific securities nor is he responsible for comments made by persons posting on this blog.

Read the full article →

Foreclosures Reduce A Home’s Value By 27%, MIT Study Finds

July 21, 2010

Thinking about defaulting on your mortgage? You might be putting a serious damper on the value of neighbor’s home. A single foreclosure can decrease value of homes within 250 feet to drop by an average of one percent, according to a recent MIT study . The study, which examined 1.8 million home sales in Massachusetts from 1987 to 2009, also found that the typical foreclosed home has its post-foreclosure price slashed by an average of 27 percent. (That number tends to be larger for houses with “low-priced characteristics in low-priced neighborhoods,” the study found.) By contrast, the authors note, if a house is sold after the death of an owner, the value drops five to seven percent. If a homeowner declares bankruptcy, the study shows, the price only falls three percent. Why do foreclosures cause such a large decline in a home’s price relative to other kinds of forced sales? In the study’s working paper, MIT economist Parag Pathak and two Harvard researchers, John Y. Campbell and Stefano Giglio say that foreclosed houses sell at such low prices “both because they may have been physically damaged during the foreclosure process, and because financial institutions have an incentive to sell them quickly.” Read the whole report below: Forced Sales –

Read the full article →

Jeffrey Hollender: And the Survey Says: Sustainability Key to Future Business Success

July 19, 2010

A  new study on sustainability  by Accenture and the UN Global Compact*  affirms what I have been preaching for the last two decades, that sustainability is critical to a business’s future success. The largest study of its kind showed that 93 percent of UN Global Compact CEOs agreed with the importance of a sustainability strategy for their own companies. What was the biggest motivator for these CEOs to take action on sustainability issues? Not surprisingly, “strengthening brand, trust, and reputation” was identified by 72 percent of the respondents. And it’s no wonder, with BP and Toyota being the 2010 poster children of what can happen when core values of responsibility and sustainability aren’t infused into the culture and job description of every employee on payroll. In fact, many of the 766 CEOs who responded believe that “business that is both sustainable and profitable requires efforts by people at all levels of the corporation.” A fundamental shift since the last Global Impacts study in 2007, this recognition by CEOs is significant, and hopefully is the harbinger of real change to the business-as-usual attitude that we’ve become accustomed to seeing. On a broader scale, the study revealed that business is taking sustainability more seriously and there is strong belief that, within the decade, a tipping point will be reached that brings sustainability from the periphery to the core. The CEOs surveyed have finally recognized that having a siloed sustainability initiative, while fodder for the annual report, will not in actuality get them very far. Instead, sustainability will need to be embedded into everything from corporate mission to operating strategy and tactical execution. As Bill Breen and I discuss in our recent book, The Responsibility Revolution , being a genuine socially and environmentally responsible company will be the only way to compete and win in the 21st century. Nike, one of the companies we profiled in our book, has undertaken just this kind of radical change. Nike’s long slog on the road to improving conditions in its contract factories, combined with some early but limited successes in recycling and green chemistry, led it to conclude that incremental change is a woefully inadequate response to the environmental and social problems that all companies face. Thus, their sustainability team was charged with putting the sustainability ethos at the heart of what Nike does, which is innovation and design. The decision was made to create products that live and breathe sustainability. Nike determined that the CR team needed to work at the beginning of the innovation pipeline, where strategy is set and creativity occurs, rather than at the end, where outcomes are audited and after-action CR reports are filed. They accomplished this by changing their thinking. Instead of treating sustainability as a compliance or risk-management function, the CR team acts as an idea lab that pushes innovation, but at the same time allows business units to ”own” sustainability and include it in their day-to-day work. Nike also took advantage of technology to help designers make sustainable choices at the beginning of the process. The company’s think tank has created a predictive tool that quantifies, in real time, the ecological impact of each and every one of the designers’ choices: it’s a desktop program called the Considered Index. The index allows Nike to make every designer an agent of sustainability. When they see that a better score can be achieved by reducing adhesives, which emit VOCs, they develop snap-together tooling that completely eliminates adhesives. The designers chip away at their overall environmental impact, one decision at a time. So how does a company change gears like Nike has and move their workforce from outdated, shortsighted habits to new sustainable methods of doing business? Certainly guidance and inspiration from the C-Suite is key. But 86% of CEOs concurred that they must increase their investment in management training for sustainable strategies and operations. One approach to delivering this type of training cost effectively is The Sustainability Institute , an online learning portal developed by Kaplan Eduneering and Seventh Generation that helps companies understand corporate responsibility and weave it into their corporate practices. Companies wishing to stay ahead of the sustainability curve and impending government mandates would be wise to research training, consulting, and software options that enable them to make the transition as swiftly and profitably as possible. *The United Nations Global Compact is strategic policy initiative for businesses that are committed to aligning their operations and strategies with ten universally accepted principles in the areas of human rights, labor, environment and anti-corruption. Jeffrey Hollender is the co-author of the recently published book, The Responsibility Revolution . The Co-Founder and Executive Chairman of Seventh Generation , and a Co-Founder of the American Sustainable Business Council and the Sustainability Institute , Hollender also shares his insights at The Inspired Protagonist , a leading blog on corporate responsibility.

Read the full article →

Raymond J. Learsy: Natural Gas Replacing Coal Fired Power Plants- A Major Step Toward Diminishing CO2 Emissions

July 14, 2010

Last week at an Aspen Institute Ideas Festival session Marvin E. Odum, the President of Shell Oil was in conversation with Andrea Mitchell. The major theme of the day was, of course, the Gulf Oil disaster, how it might have been prevented, steps to be taken in the future, topics of urgent and immediate importance. In the course of the discussion Mr. Odum brought into focus another important issue. The role that natural gas should play in the abatement of CO2 emissions. He made the audience aware of the newly defined and abundant deposits of natural gas termed as ‘shale gas’ accessed through novel techniques of horizontal drilling and hydraulic fracturing. He went on to discuss the potential of this new resource abundance were it to be used as a substitute for coal, replacing in significant measure, coal fired power generating plants and what it would achieve in the abatement of greenhouse gas emmisions. According to Mr. Odum, converting from coal to gas fired electricity plants would eliminate 50% to 70% of current CO2 emissions depending on the coal burning systems being replaced, and therefore an issue that needs come to the forefront of our Energy policy (pleae see “Our Lob(otomized)bied Congress’ Energy Bill Excludes Our Most Efficient, Cleanest, Newly Plentiful Energy Source: Natural Gas” 06.28.09). Mr Odum advised that Shell has just committed $5 billion to taking an important stake in the Marcellus Shale, a staggeringly rich shale gas field containing some 500 trillion cubic of gas that lies within the Appalachian Basin extending from eastern Ohio, West Virginia, Pennsylvania and into New York State. Mr. Odum further advised that Shell was fully aware of the environmental issues related to shale gas drilling such as the risk os shallow fresh water aquifer contamination yet Shell is confident the environmental impact issues can be managed through careful and fully transparent procedures to the satisfaction of government and oversight agencies, policies his company will follow rigorously and that oversight agencies need enforce universally. Coincidently just over a month ago the Massachusetts Institute of Technology’s MIT Energy Initiative issued a singularly informative report, informative to all interested in the subject of fossil fuel consumption, its environmental impact and desirous of having a hands on understanding of one of the key elements that will unquestionably be at core of the nation’s energy future. Its dimension and importance were made clear from the very outset as MITEI Director ErnstJ.Moniz introduced the report stating: -”Much has been said about natural gas as a bridge to a low carbon future, with little underlying analysis to back up this contention. The analysis in this study provides the confirmation – natural gas truly is a bridge to a low carbon future” The report, a comprehensive review clearly brings into focus the future importance of natural gas as an element of the fossil fuel equation. The study shows a baseline global estimate of recoverable gas resources reaching some 16,200 trillion cubic feet (Tcf), enough to last over 160 years at current global consumption rates. The report was conducted by a study group of 30 MIT faculty members, researchers and graduate students. It is publicly available at: rhttp://web.mit.edu/mitei/research/studies/naturalgas.html It is will be well worth your while to access this important study where there is an interest in the future of fossil fuel consumption and their environmental impact.

Read the full article →

David Isenberg: Out of Sight Should Not Mean Out of Mind

July 13, 2010

Last month Michael H. LeRoy, Professor in the School of Labor and Employment Relations and the College of Law at the University of Illinois at Urbana-Champaign, published a new study: ” The New War Labor Paradigm: Civilians Who Work Like Soldiers and Soldiers Who Work Like Civilians– How to Compensate for Death And Injuries? ” He examined the legal remedies that are available for soldiers and their civilian counterparts who are injured or killed in war zones. He identified tort claims and workers’ compensation claims filed by both civilian employees and military personnel against private military firms and examined the outcomes of such litigation. While he found it promising that courts have been willing to reject the immunity defenses asserted by private military firms, something I have written about previously , and allow trials, he still believes policymakers need to build a system that better compensates and addresses the claims of the civilian employees and uniformed military personnel. To the extent most people think of these issues, if they think of them at all, people assume these issues are dealt with by the Defense Base Act, which is essentially workers compensation mandated by federal law for all contractors whose employees work overseas. But, in truth the reality is more complex. According to LeRoy: Co-mingling military service and civilian labor raises new questions about legal remedies for Americans who are killed or injured serving their country. Consider the Halliburton truck drivers who delivered supplies to U.S. troops in Iraq. Six were killed after their convoy was ambushed in 2004. The day before, a similar convoy was attacked, killing a co-worker. The drivers contemplated a work stoppage until conditions were safer. Bowing to work orders, they met their fate (Flood, 2009). Survivors believed that job ads misrepresented the safety of work in Iraq. A judge rejected Halliburton’s defense that it has immunity from suits as a government contractor. Thus, the survivors’ legal claims are proceeding to trial. Consider a reciprocal case, where soldiers served on a non-combat mission under a civilian contractor. As they worked at an Iraqi water treatment plant, they developed bloody noses– a sign of poisoning from the sodium dichromate in pipes (Searcey, 2010). Fearing long term effects from this deadly toxin, the soldiers sued KBR. An Indiana court will decide whether their claims are dismissed under the Feres doctrine– a legal principle that bars tort recovery for injuries that arise during military service. Death- and injury-benefit cases do more than raise technical legal questions. When courts award or deny monetary relief in these war labor cases, they decide whether civilians and soldiers perform “work” or “service.” The distinction has profound consequences for compensating war losses. LeRoy draws a distinction between private military firms and other military contractors. The labor relations practices of PMF firms differ from other defense contractors. Boeing and Lockheed-Martin have union-represented employees. But firms such as Halliburton strongly resist unions (Halliburton Co., 1963; Halliburton Co., 1968; Freightmaster, Div. of Halliburton, 1970; Halliburton Services, 1977). They also avoid judicial accountability by requiring workers to arbitrate disputes (in re Halliburton, 2002). Certainly, other companies use union-suppression and litigation-avoidance strategies. But PMF firms differ by leveraging their close ties to government insiders (e.g., an Army Corps of Engineers officer lost her job after she objected to a large, no-bid contract to Halliburton [Eckholm, 2004; Witte, 2005]). In short, private military firms use a war labor model that insulates them from external accountability. They do not deal with unions or courts, and they use political influence to avoid public accountability. Prof. LeRoy suggests the following as possible public policy options. ● Option 1: Preserve the Status Quo. The present method for resolving death and injury claims does not necessarily need to change. Most civilians and service members are able to try cases in civil law courts. This means that judges are open-minded in responding to the new war labor paradigm. In other words, courts are not dismissing complaints simply because incidents occurred: (a) outside the U.S., (b) in active combat zones, and (c) in conjunction with military command. These three points are remarkable given that courts usually dismiss liability suits against contractors by applying immunity doctrines. In sum, courts are grappling with the new war labor paradigm but have ponderous methods to rule on claims. ● Option 2: Create a Federal Worker’s Compensation Policy for Civilians Who Work as Private Military Forces. Worker’s compensation is an insurance system to replace lost wages, reimburse medical expenses, and provide a death benefit for workplace injuries. Called the grand compromise, it provides injured workers a timely remedy but also insulates employers from liability for damages, including costly punitive awards. The strict liability feature of worker’s compensation would avoid the complex issues of causation that arise in war zone cases. The complexity is due to the joint control between military commanders and civilian managers. A strict liability system would simply compensate injuries and deaths that arose in the course of employment. Fault would be irrelevant. This would reduce the need for court adjudication. The fact that PMFs are employed by private firms strengthens the case for worker’s compensation. Ordinarily, all employers must provide for this benefit as a matter of law. ● Option 3: Encourage Extra-Territorial Application of Current State Worker’s Compensation Laws. … Worker’s compensation laws that reach beyond the state’s borders would avoid messy tort litigation while paying appropriate benefits to private military forces employees. ● Option 4: Improve the Compensation System for Soldiers Who Are Killed or Injured While Serving with Private Contractors: In 2008, a federal program paid about $4.7 billion every month to the survivors of Americans who died as a result of a service- connected disability (U.S. GAO, Military and Veterans’ Benefits (2009(b)). In the Veterans’ Benefits Improvement Act of 2008, Congress asked the GAO to compare these benefits to those for survivors of federal civilian workers. The report found military benefits were far less than those paid to civilians under federal worker’s compensation. This result suggests that a supplemental benefit should be considered for soldiers who die or are injured while working with a contractor. The theory behind this idea is that a service member’s labor is co-mingled with the contractor’s workforce. Thus, the soldier’s labor contributes value to the contractor’s service. In other words, when the integration of military and civilian labor creates commercial value, contractors might contribute to a fund that supplements these service member benefits. If funding were tied to experience ratings, contractors would be encouraged to adopt safer practices. Prof. LeRoy’s study illustrates the not infrequent examples of PMC worker and soldier vulnerability to PMC misdeeds, whether intentional or unwitting. In the old days workers had a solution for that. It was called a union. I can already hear PMC CEO’s screaming that unions are clearly inapplicable. But are they? Here is what Prof. LeRoy writes: My study presents a picture of worker vulnerability. It also sheds light on employers who neglect worker safety. Recall that convoy drivers thought about striking after their co-worker was killed the day before in a similar assignment. Two women were sexually assaulted at work– and then were locked up, interrogated, and harassed by their employer. These are settings where union voice is relevant. Unions already represent employees who work for defense contractors. Is Halliburton so different from Boeing? Prof. LeRoy’s bottom line is this: Overall, the integrated work performed by these civilians and soldiers exemplifies the aphorism “out of sight, out of mind.” My research suggests that these employees and soldiers deserve better treatment. The fact that they are fighting a war in a distant corner of the world is no reason to shortchange them. When private companies seek to profit by directing this employment and service, the veil of government immunity should be removed– or at least curtailed. The present system imposes disproportionate costs on severely injured workers and soldiers, and their survivors. The lack of accountability for negligence, recklessness, intentional injury, and severe discrimination is at odds with military principles of discipline and order. In sum, the deaths and injuries that are at the heart of this study expose the shortcomings of the private military force strategy. As such, they also offer valuable lessons for improving this integrated war labor model.

Read the full article →

Robert F. Brands: Do Your Innovation Emperor, Rules & Idea Management Help or Hinder the Process?

July 6, 2010

In the pursuit of innovation, many “enlightened” companies try to follow what they believe are established morays and best practices. They install someone to manage new product development or innovation. They set up a litany of rules. And they select only the “best” ideas for further development. Then they wonder why innovation falls fallow. A recent study from The Nielsen Company found that companies with acknowledged, successful innovation practices also have limited involvement from senior management. The teams are guided, but freed of stifling controls. With the premise, “Manage Ideas Lightly, Manage Process Precisely,” the study of 30 top consumer and package goods companies found that ideation and new product development must be structured, but unconstrained. The companies enjoyed 80% more new product revenue when senior executives were less involved in managing innovation. The study also found that the companies realized 130% more new product revenue with less rigid “stage gates” or measurable reporting goals along the way. In short, smart companies — Apple, Starbucks, Whole Foods and IBM, for example — have an innovation, an environment that removes the constraints and welcomes a free flow of ideas, noted Tom Agan, the Nielsen SVP and managing director who presented “Renovating Innovation” at Nielsen’s Consumer 360 conference in June. “One of the keys to successful new product innovation is to manage new ideas lightly,” Agan was quoted in DrugStore News. While we don’t dispute senior management’s strengths and good intentions, they are often too quick to get involved in the creative process, especially when things are not going well, and their mere presence can stifle free-thinking and boundary-less ideas — which can doom the new product development process to failure. I agree — to an extent. This is much of what “Robert’s Rules of Innovation” espouses from its inception. To be sure, meddling leadership can stifle the process. But effective innovation thrives under the guidance of a CEO or Chief Innovation Officer , supported by the Board, with the authority to provide the air cover needed to protect unfettered (but deliberate) innovation, and the soft hand to foster creative, imaginative innovation. Any and all ideas should be welcomed, Open Innovation from the inside as well as outside and fed into an innovation Idea Hopper , where they can be further developed, if not in the near-term, then when market conditions or forces allow for such development. The limited involvement of management is the real gem in Nielsen’s findings. While the CEO is the best possible champion for any company’s innovation strategy (after all, support at the highest level generally helps ensure adherence to vision, mission, strategy and ultimately resources), such support also must encourage lower and mid-level management’s embracing of the concept the CEO or CIO is selling. With objective and not to be forgotten reward systems and incentives aligned, pursuits have the highest chance of taking root. Agan also noted the need for stage gates and scorecards to measure results. In fact, observation and measurement is essential to effective innovation. Such deliberate focus provides consistency and keeps teams on target and accountable. The removal of stage gates can help expedite and foster unfettered innovation, as long as the required steps are still incorporated. Yet this only works if such blossoming of ideas is followed by deliberate pruning and cultivating to ensure the best ideas are pursued at the best possible moment, which — in turn — ensures the best possible opportunity for commercialization or market exploitation. The challenge for the CIO or Emperor, especially in larger companies, remains to encourage hearty pursuit of innovation — without meddling by VPs, who have full plates, unique silos or fiefdoms, and objectives and rewards that often are contradictory to the very premise of the innovation goals. Such mis-alignment can kill innovation. Instead, an inspired Emperor must lead the charge. He or she must align agendas, and figure out and pull into line the objectives of fully engaged teams and leadership. Across the ranks, those involved in successful innovation are rewarded or bonused accordingly. Such uniformity builds consensus, helps remove conflicting agendas and can ensure. In the end, the Emperor will find himself — or herself — ruling over an empire where ideas thrive, goals are met, and innovation blossoms. Robert Brands is a keynote speaker, author of “Robert’s Rules of Innovation” and InnovationCoach with www.innovationcoach.com .

Read the full article →

Steve Parker: Why Is Ford So Successful?

July 2, 2010

During the past year, General Motors went bankrupt, Chrysler found itself owned by Italy’s Fiat. Yet Ford seems to be hitting home runs, knocking them out of the park with regularity. In fact, all of Detroit fared alright in the recent J.D. Power Initial Quality Study (IQS), the benchmark for quality in the auto industry. It measures “problems per 100 cars” as reported by owners who have had the cars for 90 days. New 2009 vehicles sold by Chrysler, Ford and GM’s domestic brands have improved in initial quality by an average of 10 percent, compared with 2008, surpassing the 8-percent rate of improvement by the industry overall. Imports still garnered the most segment awards from Power, but the IQS shows that the quality gap is still closing between domestics and imports, and things are moving in the right direction for Detroit. This is pretty remarkable considering the miserable, nightmarish condition of the industry the past two years. For quality to continuously improve speaks volumes about parts suppliers, assembly line workers, the factories where they toil and the stylists, engineers and designers who have all come up with some of the best cars and trucks the marketplace has ever seen. All new Taurus Ford won three of the IQS segment awards, the Mercury brand one. Ford’s unique Edge tied for first place with Chevy Trailblazer and Toyota 4Runner in the Midsize Multi-Activity Vehicle segment. In the Midsize Sporty category, Ford’s 2009 Mustang got the highest marks and in large pickups, the ubiquitous Ford F-150 took home the top honors for the Dearborn, MI-based car maker. While Ford did best among the domestics in the 2009 IQS, another announcement they made this past week also spoke to the company’s recent success. That news was Ford will pay about $3.8 billion in cash to a union health-care fund, a sign the automaker is confident that CEO Alan Mulally’s focus on the namesake brand will produce profits. Ford sales rose 13% in June of this year over June, 2009. There are signs, though, that consumer confidence may be getting shaky again and the industry overall might be in line for another recession-based loss of sales and profits. But in the meantime Ford is flying relatively high, and it’s not just all about the product. 2011 Ford Fiesta In late 1989, Ford paid nearly $2.5 billion to acquire Jaguar, then a long-suffering car maker whose future looked none too bright. Legendary poor quality had dogged Jaguar for decades, and they didn’t have the money or the technology to make a fresh start with all-new models. Ford also bought Aston Martin (1994) and Range Rover (2000). All three companies improved in quality and customer service after their purchase, though a friend of mine still describes Range Rover interiors as looking like “an unfinished high school metal shop project”. In fact, in one of the first Power IQS surveys in the early ’90s, Jaguar was named the top brand in the world based on its improvement in the study, while the company had been near-last before the Ford purchase. Those buys by Ford came in handy before the worst of the recession hit. In mid-2008, Ford got $2 billion while off-loading both Jag and Range Rover to India’s Tata, maker of the super mini Nano which has gained much attention worldwide for its small size and even smaller price. Ford was also able to sell Aston Martin to a consortium of engineers and racers (and banks). Jaguar’s brand win was the first time people took a very serious look at the Power IQS and helped establish the J.D. Power brand with the public just as Power’s survey results created a new life for Jaguar. Power had developed a method which, for the first time, quantified quality, giving the public a one-stop shop for determining the likelihood of problems with a particular car or truck. Ford’s 2010 Super Duty F-250 Power does not test cars; it uses registration rolls from every state to survey a set amount of owners of most all makes and models sold in the U.S. For this IQS, Power says they just spent nearly six months sifting through more than 80,000 surveys conducted with verified owners of 2009 model year vehicles. Ford’s Fusion line-up (which includes a hybrid), the all-new Taurus and Euro-bred Fiesta and of course that F-150 truck are keeping Ford on the up side. Creative marketing (such as their tie-in with American Idol and the company giving new models to under-30 types before they’re on-sale) have also been top drawer, currently some of the best in the business. Ford had one other win in the Power IQS. That was the Mercury Sable, the gussied-up version of the Taurus. It won in the Large Car segment, gaining traction with the 2009 model from 2008, when it placed second in class. Of course the irony is that Ford has officially killed their Mercury division, slating it to be gone within the next two years. Ford Transit Connect

Read the full article →

Video: Colas Says Book Choices Are a Viable Economic Indicator: Video

June 25, 2010

June 25 (Bloomberg) — Nicholas Colas, chief market strategist at BNY ConvergEx Group LLC, discusses his study of the correlation between best-selling book topics and the health of the U.S. economy. Colas speaks with Betty Liu on Bloomberg Television’s “In the Loop.” (Source: Bloomberg)

Read the full article →

Barney Frank Secures Win For Investors, Beats Back Senate

June 24, 2010

House Financial Services Committee Chairman Barney Frank successfully fought back Thursday against a Senate proposal that would have scrapped an Obama administration-supported measure to protect Main Street investors from unscrupulous brokers on Wall Street. The Senate proposal, pushed by Sen. Tim Johnson, Democrat from South Dakota, called for a study to examine whether brokers — middlemen between sellers and buyers of securities — should act in the best interests of their clients when peddling securities and investment advice. Investment advisers are held to this standard, known as a fiduciary duty. Yet brokers for Wall Street firms, even when performing the exact same function, currently are not. Johnson’s measure, though, went a bit further by also setting a high bar for the Securities and Exchange Commission to clear in order to actually implement new rules aimed at protecting retail investors. In short, the SEC would have to determine that virtually every other alternative to protecting average investors from broker-dealers is inadequate before the agency would be allowed to level the playing field between brokers and advisers, and protect retail investors. Investor advocates blasted Johnson , and the Senate conferees negotiating the final financial reform bill, for adopting the proposal late Tuesday. Frank, however, was able to persuade Johnson and his Senate colleagues to support the House version of the same provision. Conferees from both chambers adopted the measure, ensuring its place in the final bill. Frank’s proposal also calls for a study, to be conducted over six months, yet allows the SEC to work on developing new rules while simultaneously studying the issue. So while the SEC is conducting its study it can also work on developing the new rules and all that entails federal agency rule-making, like holding hearings, conducting analysis and soliciting public comment. At the end of that six-month period, the SEC can then quickly issue the new rules. The only caveat is that the rules would have to incorporate the findings of the study. The compromise brokered by the Massachusetts Democrat ensures that the issue will be studied — a priority of Johnson’s — while also giving federal securities regulators the authority to protect investors on Main Street. SEC Chairman Mary L. Schapiro has already publicly supported such a new rule; two fellow SEC commissioners also are known to support subjecting brokers to a fiduciary standard. Together they form a majority on the SEC’s board, perhaps ensuring the final rule’s passage. In addition to Schapiro, investment professionals and investor groups, the North American Securities Administrators Association, the National Association of Secretaries of State, AARP and the Consumer Federation of America also support the measure. The Obama administration advocated compelling brokers to act in retail investors’ best interests last June in its 89-page blueprint for reforming the nation’s financial system. The House included it in its financial reform bill that passed in December. The Senate version, passed last month, called for a study. “Chairman Frank said at the start of this process that fiduciary duty was a priority for him, and he really came through,” said Barbara Roper, director of investor protection for the Consumer Federation of America. “The final agreement fully addresses the concerns we had raised about the Senate offer. “It provides the SEC with full authority to impose the Advisers Act fiduciary duty on brokers when they give investment advice, and it removes the impediments that would have prevented the agency from doing so. This is a major win for investors on an issue that has been a priority for literally decades,” Roper continued. She added: “It is a real achievement that Chairman Frank was able to bring this over the finish line, and we are grateful that Sen. Johnson was willing to agree to the compromise and allow this to move forward. “Now it will be up to the SEC to ensure that this is implemented in the way investors deserve. For that to happen, Chairman Schapiro will need to ride herd on SEC staffers who have previously sunk efforts to strengthen investor protection in this area.”

Read the full article →

Jack Buffington: What Do We Mean When We Assert That Our Economic Salvation Is ‘Innovation?’

June 22, 2010

‘Innovation’ is commonly cited as an American economic strength. At the same time, there is disturbingly powerful evidence that too many Americans lack a clear understanding of the innovation process. Although in America there has been a remarkable confluence of innovation and industrial economic growth, the process itself is in no way haphazard. Today, the American model of industrial innovation is being deployed very effectively in Europe and Asia, just as the system atrophies in the U.S. I know this to be true first hand as a corporate manager for a Fortune 500 U.S. company, a doctoral researcher for a university in Sweden, and someone competing largely against Asian researchers in my study of discontinuous innovation. Sweden is second only to Israel in its public funding of R&D per capita, and China has doubled its investment in its university system over the past ten years while at the same time, the U.S. has declined in both measures. I see firsthand how innovation is stimulated by a necessary set of interactive factors, and that it is simply not possible to specialize in R&D. It is misguided for anyone to believe that America can position itself as the world’s expert and specialist in R&D for the global economy; there is no historical evidence to justify this viewpoint for any nation. Instead, America’s industrial domination was built upon a model that tightly linked R&D and production, in the public and private sectors. After World War II, research was linked between the public sector (government and academic institutions) who were largely responsible for pure science , and the private sector that was often responsible for the applications effort that we often define today as ‘research and development’. Pure science is often misunderstood, but is a most critical initiative, leading to radical or discontinuous innovation – true drivers of economic growth. After World War II, noted scientists as Vannevar Bush helped to establish a model linking the usefulness of science to socioeconomic progress through the consortium of private firm, academic, and government institutions. One of Bush’s students, Frederick Terman, is largely credited for being the Father of Silicon Valley, an example of the benefits of linking the private sector, government, and academia in the development of innovation. Today, this American innovation model has been repackaged and is now being called the triple helix model of innovation. Lack of American understanding of this triple helix approach is illustrated by the dot-com boom of the late 1990′s. While most Americans would associate the free market heyday as an illustration of American innovation, most of us would struggle in believing that it was collaboration between government, academia, and the private sector that actually originated it. I believe this is due to our generalization that anything related to the private sector can lead to innovation, even the outsourcing of production and R&D, while anything associated with the government and/or academic institutions cannot. As a result, America’s unbalanced model of R&D and production is actually moving us away from innovation instead of closer to it. With academic research finding that it takes 3,000 raw ideas, 100 exploratory projects, 10 well funded projects, and 2 product launches to create one successful innovation, few corporations will put itself through this process due to a lack of positive return on investment. However, it’s in the best interest of the public sector enable private sector research within its national boundaries to become a possible engine of economic growth. Countries such as Sweden, Norway, and Denmark are utilizing this model of innovation successfully, while Americans commonly consider these countries to be less innovative. Asian economies are beginning to understand this public – private approach as well – the old American innovation process, not the new. Through outsourcing production and ignoring the role of the public sector in the innovation process, America is misappropriating something of its own invention. The evidence is overwhelming that America is heading in the wrong direction: our history tells us we are misguided, and the rest of the world is following a different course. I see this first-hand in conducting innovation research in Europe and in competition with increasingly competent Asian researchers. Politics aside, failing to see that the rest of the world has adopted an approach that American pioneered, and from which we have veered, will without question reduce the likelihood of the next Silicon Valley being in California rather than Stockholm, Bangalore or Shanghai. In my mind, there is no more critical issue facing the U.S. economy than the need to fix our approach to innovation.

Read the full article →

Foreclosure Epidemic Hits Minority Communities The Hardest: Center For Responsible Lending

June 18, 2010

The foreclosure crisis has been much harder on African-Americans and Latinos, according to a new study by the Center for Responsible Lending (CRL) . “African American and Latino borrowers have borne and will continue to disproportionately bear the burden of foreclosures,” asserts the CRL. Based on its estimates, nearly 8 percent of both African American and Latino borrowers have lost their homes to foreclosures, compared to 4.5 percent of white borrowers. Further, African-American and Latino borrowers are 76 percent and 71 percent more likely, respectively, than white borrowers to have lost their homes to foreclosure since housing prices started to tumble in January 2007. From early 2007 to the end of 2009, the study estimates the completion of 2.5 million foreclosures and the origination of 6.9 million foreclosures across all races. In identifying reasons for the disparate impact of these foreclosures on communities of color, the CRL says: “African-American and Latino borrowers were particularly vulnerable, as originators targeted traditionally underserved communities for subprime loans and steered borrowers of color to higher-cost loans. Indeed, court cases and information provided by former employees of subprime lenders describe the systematic targeting of African-American neighborhoods and other communities of color.” The study also cites previous CRL research that shows African-American and Latino borrowers to be 30 percent more likely to get higher-rate subprime loans than white borrowers with similar risk characteristics. This may be another reason why, according to the CRL, 575,000 African Americans and Latinos have lost their homes since 2007 and 1.2 million are currently two or more loan payments behind on their mortgage. Read the report HERE: foreclosures-by-race-and-ethnicity –

Read the full article →

Foreclosure Epidemic Hits Minority Communities The Hardest: Center For Responsible Lending

June 18, 2010

The foreclosure crisis has been much harder on African-Americans and Latinos, according to a new study by the Center for Responsible Lending (CRL) . “African American and Latino borrowers have borne and will continue to disproportionately bear the burden of foreclosures,” asserts the CRL. Based on its estimates, nearly 8 percent of both African American and Latino borrowers have lost their homes to foreclosures, compared to 4.5 percent of white borrowers. Further, African-American and Latino borrowers are 76 percent and 71 percent more likely, respectively, than white borrowers to have lost their homes to foreclosure since housing prices started to tumble in January 2007. From early 2007 to the end of 2009, the study estimates the completion of 2.5 million foreclosures and the origination of 6.9 million foreclosures across all races. In identifying reasons for the disparate impact of these foreclosures on communities of color, the CRL says: “African-American and Latino borrowers were particularly vulnerable, as originators targeted traditionally underserved communities for subprime loans and steered borrowers of color to higher-cost loans. Indeed, court cases and information provided by former employees of subprime lenders describe the systematic targeting of African-American neighborhoods and other communities of color.” The study also cites previous CRL research that shows African-American and Latino borrowers to be 30 percent more likely to get higher-rate subprime loans than white borrowers with similar risk characteristics. This may be another reason why, according to the CRL, 575,000 African Americans and Latinos have lost their homes since 2007 and 1.2 million are currently two or more loan payments behind on their mortgage. Read the report HERE: foreclosures-by-race-and-ethnicity –

Read the full article →

Record Prescription Drug Overdoses in U.S. Match Total of Heroin, Cocaine

June 17, 2010

By Tom Randall June 17 (Bloomberg) — Emergency-room visits from abuse of prescription and over-the-counter medicines doubled in the U.S. in four years, matching for the first time the number of overdoses of illegal drugs such as cocaine and heroin. Regulator-approved treatments were implicated in a record 1 million patients who sought help at hospital emergency departments in 2008, twice the number as in 2004, according to a study released today by the Centers for Disease Control and Prevention, in Atlanta. Overdoses from illicit drugs were unchanged, at 1 million emergency visits. The most hospitalizations were caused by painkillers, with visits more than doubling, and tranquilizers, with an 89 percent increase. King Pharmaceuticals Inc. , in Bristol Tennessee, and Purdue Pharma LP, in Stamford, Connecticut, won approval in the last year for drugs to prevent misuse. A half-dozen drugmakers are developing pain pills that resist abuse methods such as crushing, dissolving in alcohol, and taking more than needed. “Additional measures are needed urgently,” researchers wrote in the CDC’s Morbidity & Mortality Weekly Report. “Recent public health and law enforcement measures intended to prevent nonmedical use of such drugs have not prevented rate increases.” The biggest increase in emergency visits was from adults in their 20s, according to the study. The researchers analyzed reports from 220 emergency departments across the U.S. to estimate the nation’s tally. To contact the reporter on this story: Tom Randall in New York at trandall6@bloomberg.net .

Read the full article →

Hong Kong’s Tsang Pins His Reputation on TV Debate Over Pace of Democracy

June 17, 2010

By Frederik Balfour June 17 (Bloomberg) — Hong Kong Chief Executive Donald Tsang tonight faces off in a televised debate with opposition lawmaker Audrey Eu over China’s plans for changes to the city’s electoral system in 2012. The debate with the pro-democracy leader is unlikely to win over any of the 23 legislators who vowed to block the proposals, and may be aimed more at salvaging Tsang’s reputation with the central government in Beijing, said Alan Leong , a lawmaker in Eu’s party. “Beijing is evidently not willing to give genuine and true universal suffrage to Hong Kong,” said Leong. “The purpose of the debate is for Donald Tsang to demonstrate to Beijing that he has done his utmost to get the 2012 package through.” Eu’s pro-democracy group argues that China’s package doesn’t go far enough to deliver full democracy and is stacked in favor of business groups dominating the so-called functional constituencies that make up half the 60 seats in the Legislative Council. LegCo is to vote June 23 on the proposal, which would see the number of lawmakers increased by 10. Five would be directly elected and five would represent functional constituencies. The number of Beijing appointees who elect the chief executive would be increased from 800 to 1,200. Tsang wants “to let the people have a chance to hear the arguments on both sides and come to an informed decision,” his spokesman Andy Ho said in an e-mail. Public Protest Tsang’s predecessor Tung Chee-hwa stepped down from his post in 2005, more than two years early, after a botched attempt to push through separate China-sponsored constitutional changes sparked street protests and a deadly virus decimated tourism. Tsang’s own popularity has been slipping amid the wrangle over elections, polls show. On June 4, about 113,000 people attended a candlelight vigil to mark the 21st anniversary of the crackdown on pro- democracy demonstrators in Tiananmen Square, the largest number since 1989 according to police estimates. Chinese President Hu Jintao in December told Tsang to “handle constitutional development issues properly to ensure social harmony.” Premier Wen Jiabao urged him to resolve “deep-rooted contradictions in Hong Kong.” Beijing’s Timetable One of those contradictions is the “one country, two systems” formula struck when Britain handed the territory back to China in 1997. While Hong Kong has multiple political parties and more civil liberties than in mainland China, the timetable for greater democracy was set by the National People’s Congress Standing Committee in Beijing. Eu is calling for universal suffrage in 2012, five years earlier than China’s plans for letting the public vote for the chief executive and eight years before planned direct elections of all LegCo members. Twenty-three of the 60 LegCo members have already said they’ll oppose the 2012 package, which needs a two-thirds majority to pass, unless China makes concessions. While the city’s lawmakers discuss issues ultimately decided in Beijing, a growing number of Hong Kong’s 7 million people are expressing frustration at issues such as growing income inequality and air pollution. “We are structured not like a city, but like a country,” said Christine Loh , Chief Executive Officer of Hong Kong-based think tank Civic Exchange . “All the stuff relating to city planning, city design, city transport and things concerning public health, dealing with markets, public space and gardens, heritage preservation doesn’t dovetail very well.” Unsatisfied Citizens Results of a random survey of 934 households conducted by the Hong Kong Transition project between June 4 and June 14 indicate a majority of the respondents “express dissatisfaction with the Chief Executive’s performance,” said Michael DeGolyer , a professor of government and international studies at Hong Kong Baptist University , who heads the study. Sixty-three percent of respondents favored the abolition of functional constituencies representing key industries such as banking, law and manufacturing. That’s up from 55 percent of those polled from May 6 to May 15. “A lot of people are connecting the business domination of the functional constituencies with unfair policies they are experiencing,” said DeGolyer. The number of people living in poverty in Hong Kong in the first nine months of last year rose 19 percent, the South China Morning Post reported May 12, citing government data. Record Pollution Pollution in Hong Kong soared off the scale on March 22 as winds from sandstorms in northern China carried particles to Hong Kong. The air quality had never been so poor. The government denied the democracy debate is distracting efforts in other areas. “The electoral problems are the most pressing,” said Donald Lam, a spokesman for Tsang’s office. “It doesn’t mean the government is ignoring other problems.” In March, Secretary for the Environment Edward Yau said Hong Kong may accelerate replacement of old buses, change transit routes and set up low-emission zones to cut pollution. Still, it will take almost a decade to eliminate outdated buses from the city’s roads, he said. “Our toxic air is the most damning symptom of our present political system,” said Joanne Ooi , chief executive officer of independent advocacy group Clean Air Network . “Although the public near unanimously supports the aggressive clean-up of our air, the government has consistently failed to act.” Editors: Ben Richardson , Dirk Beveridge . To contact the reporter on this story: Frederik Balfour in Hong Kong at fbalfour@bloomberg.net

Read the full article →

Gene Therapy Shows Promise for Blocking HIV, Controlling AIDS, Study Says

June 16, 2010

By Rob Waters June 16 (Bloomberg) — Two cutting-edge medical technologies, stem cell transplantation and gene therapy , were combined in an attack on the AIDS virus that may lead to new strategies for treating people infected with HIV. Researchers at the City of Hope , a nonprofit research institute near Los Angeles, extracted stem cells from the blood of four people with AIDS-related lymphoma, a blood cancer, and modified some of them to carry anti-HIV genes. The altered cells were returned to the patients’ blood without harming them and remained there for two years, a sign that if given in greater number, they might be able to suppress the AIDS virus. The results may help researchers hunting for ways to cure HIV patients or block the AIDS virus without putting people on toxic medicine for the rest of their lives. Potent antiviral drugs suppress the virus and allow those infected to live near- normal lives. Yet the medicines are unaffordable to millions in poor countries and cause side effects that may shorten the lives of people who use them. “One of the problems with antiviral therapy is that it has almost led to the perception that HIV is cured and that’s not true,” said David Schaffer , a professor of bioengineering at the University of California, Berkeley, who co-directs the school’s stem cell center. “If you could develop a therapy to make HIV-proof blood cells, then you could create a true cure for HIV. This is a very promising clinical trial that takes us in that direction.” Schaffer, who was not involved in the research, wrote a commentary accompanying the study. Both were published today in the journal Science Translational Medicine . Current Treatments More than 34 million people worldwide are infected with HIV, the virus that causes AIDS, and about 2 million lost their lives to AIDS in 2008, according to the World Health Organization , based in Geneva. Efforts to develop vaccines to prevent high- risk people from becoming infected have so far failed, leaving the drug cocktails made by companies led by Gilead Sciences Inc. , based in Foster City, California, and London-based GlaxoSmithKline Plc as the method of treating people with HIV. The City of Hope research builds on an experiment reported last year by a German doctor, Gero Hutter, in the only known case of an AIDS patient being cured. The patient, who had AIDS and leukemia, was given a stem-cell transplant from a donor whose rare gene variant caused his immune cells to lack a receptor called CCR5 . Without this receptor, HIV can’t infect immune cells. New Blood Hutter’s patient had his blood-forming stem cells wiped out and replaced by those of the donor. The transplant rebuilt his blood system and cured his leukemia. His immune cells also became resistant to HIV, allowing him to stop the antiviral drugs he’d been taking for 10 years. Three years after the transplant, the patient still has no detectable HIV, Hutter said in a June 5 interview. The City of Hope researchers extracted patients’ blood- forming stem cells, genetically modified some of them and infused them back into the patients after first wiping out their bone marrow and blood system. The modified cells were altered using a harmless virus to carry three different gene sequences into them. This triple- therapy approach was modeled on drug cocktails that attack HIV in multiple ways to overcome drug resistance, study leader John Rossi said in a June 14 telephone interview. One of the molecules cuts the CCR5 sequence in an effort to bar the door to a cell and keep HIV from entering, the second squires away a protein that the virus uses to replicate and the third knocks out a key piece of genetic machinery that HIV needs to maintain itself, Rossi said. Multiple Attacks “The idea is to hit multiple sites of the virus with different types of gene therapy so resistance to one doesn’t make it resist others,” Rossi said. “The three work better than any two together.” The transplant procedure is risky and was only attempted on HIV patients who needed it to treat their cancer. All four patients remain free of their lymphoma about two years after the treatment, Rossi said. The number of gene-modified cells returned to the patients in the study was too small to cure or even improve their HIV infections, Rossi said. The next step is to replace a much larger portion of a patient’s stem cells with gene-modified cells and see if they can substantially reduce their HIV level. Rossi and his colleagues also are exploring ways to alter the transplant procedure to make it less toxic. That may allow the procedure to be used on HIV patients who don’t have cancer. The research was funded in part by Benitec Ltd., a Melbourne, Australia-based biotechnology company that developed one of the gene therapy treatments used in the trial. To contact the reporter on this story: Rob Waters in San Francisco at rwaters5@bloomberg.net .

Read the full article →

Wall Street Bonuses Should Be Tied to Securities, Harvard’s Bebchuk Says

June 16, 2010

By Christine Harper June 16 (Bloomberg) — Bonuses for Wall Street’s top executives should be tied to a basket of the firm’s securities, including bonds and stocks, to align managers with all stakeholders and discourage excess leverage and risk, Harvard Law School Professor Lucian Bebchuk said. Under current stock-based compensation arrangements, executives are “not exposed to the potential negative consequences that large losses could impose on other contributors to the capital structure, like preferred shareholders, bondholders and depositors,” Bebchuk said in a conference call with reporters yesterday. Wall Street chief executive officers including Goldman Sachs Group Inc. ’s Lloyd Blankfein and JPMorgan Chase & Co. ’s Jamie Dimon continue to receive pay awards that are made up of restricted stock. Because banks carry more debt than equity, a better compensation system would also link executives’ pay to the performance of bonds and preferred stock, Bebchuk said. “We could tie the payoffs to executives not just to the value of common shares but to the long-term value of a broader basket of securities,” Bebchuk said. “So, for example, instead of giving executives 3 percent of the value of the firm’s common shares, you could give them, say, 1 percent of the aggregate value of the common shares, preferred shares and bonds.” Goldman Sachs, which paid Blankfein a $9 million all-stock bonus for 2009, carried about $64 billion in common equity at the end of December compared with $230 billion in preferred stock and short- and long-term unsecured debt, according to a company filing. ‘Wages of Failure’ JPMorgan, which paid Dimon $17 million of restricted stock units and options for 2009, had $157 billion in common equity compared with $330 billion in preferred stock, long-term debt and other borrowed funds, a company filing showed. Bebchuk has been a vocal critic of Wall Street pay practices. His “Wages of Failure” paper last year showed that top officials at Lehman Brothers Holdings Inc. and Bear Stearns Cos cashed in $2.5 billion in the eight years before their firms collapsed in 2008. Bebchuk said the study helped counter the “standard narrative” that compensation didn’t contribute to the financial crisis because the executives’ finances were tied to their firms’ fortunes. He made his remarks yesterday on a call hosted by the Investor Responsibility Research Center Institute , a four-year- old New York-based not-for-profit organization that funds environmental, social and corporate governance research. He spoke about three papers he has helped write about executive compensation in the financial industry. European Proposals In March, the European Parliament’s top financial lawmaker made a similar recommendation when she advocated paying bankers’ bonuses in subordinated debt rather than shares or cash to limit the type of risk-taking that contributed to the financial crisis. Sharon Bowles , chairwoman of the assembly’s Economic and Monetary Affairs Committee, said bonuses would be held for five years in a pool that the bank could use as capital to absorb losses. Bankers’ bonuses should be capped at 50 percent of their pay, lawmakers on the EU committee said yesterday, as they voted on tougher capital and remuneration rules for banks. The plan will be voted on by the whole EU Parliament in July. To contact the reporter on this story: Christine Harper in New York at charper@bloomberg.net .

Read the full article →

Adults With Leukemia Survive With Cord Blood Treatment, Research Finds

June 15, 2010

By Ellen Gibson June 15 (Bloomberg) — Adult leukemia patients who can’t find compatible donors for blood or bone-marrow cells needed for treatment may live just as long if they receive umbilical-cord blood, researchers reported in a study that may change medical practice. Patients who received cord-blood transplants had similar disease-free survival as those given cells or bone marrow from a nonfamily donor, according to research reported online today in the journal Lancet Oncology. Among patients whose disease was in remission at the time they received their transplants, 40 percent to 55 percent were alive and leukemia-free at the two- year mark, regardless of the source of the graft, the study found. While cord blood from public banks is used in children with leukemia, studies until now have shown conflicting results in adults. These findings support the use of cord-blood transplants for adults when a donor match cannot be found and when a transplant is needed urgently, the report said. “Clinicians should not waste time if it is thought that a patient is in imminent danger of progression and should move toward cord-blood transplantation,” said Paul Szabolcs , a professor of pediatrics at Duke University Medical Center, in comment accompanying the research. This report “should bolster efforts to increase the inventory of public cord-blood banks,” he added. For a leukemia patient in need of a transplant, the ideal donor is a sibling with a similar blood type. Otherwise, a non- relative with matched blood can be used, which is hard to find. Runaway Blood Cells Leukemia, a runaway growth of blood cells, starts in the bone marrow where blood cells are formed. Healthy bone marrow is transplanted into leukemia patients because it contains stem cells that help the body produce normal blood cells to replace the diseased ones. Umbilical-cord blood is another source of regenerative stem cells, one reason that many parents elect to bank their babies’ cord blood at birth. Companies involved in collecting and processing cord blood include Cord Blood America Inc. and PerkinElmer Inc. When patients search for a nonfamily donor with compatible cells, doctors may need two to three months to check the compatibility of the donor’s cells. “If it’s your first remission, you may have time to play with, but if you’ve already relapsed once, you don’t have the time to sit around for three months when umbilical cord blood is readily available,” said Mary Eapen, lead author of the study and associate professor at the Medical College of Wisconsin. “Now we know that cord blood works just as well.” Unrelated Donors For the study, researchers in the U.S. and Europe compared the survival of 165 adult patients who received cord-blood to 1,360 patients who got blood cells or bone marrow from unrelated donors who were deemed compatible based on their blood types. The cord-blood group showed a lower rate of acute graft- versus-host disease , a dangerous complication that occurs when a patient’s immune system attacks the newly transplanted material, according to the report. Yet patients who received cord blood took longer to recover and died more often from transplant- related complications than those who had other types of transplants, the paper said. To contact the reporters on this story: Ellen Gibson in New York at egibson9@bloomberg.net .

Read the full article →

Inexpensive Generic Drug May Save 100,000 Lives Annually After Accidents

June 14, 2010

By Michelle Fay Cortez June 15 (Bloomberg) — A generic drug that costs less than $10 a treatment may save as many as 100,000 lives a year by preventing people from bleeding to death after accidents, researchers said. The medicine, tranexamic acid , is widely used to control bleeding in hemophiliacs, after surgery, and by women who have abnormally heavy menstrual periods. It had never been studied for accident victims, and doctors worried that it may raise the risk of heart attacks, strokes and other complications of clots. The drug, given in two injections to patients suffering from bleeding after accidents, slashed deaths 10 percent compared with placebo, a study published today in the journal Lancet found. The medicine reduced deaths from bleeding 15 percent, without significant adverse effects, according to the research, covering more than 20,000 patients from 40 countries. “It’s probably one of the cheapest ways to save a life there ever was,” said Ian Roberts, the lead researcher, from the London School of Hygiene & Tropical Medicine, at a news conference in London. “The treatment is seriously cheap. It doesn’t get much more effective than this.” The study was funded by the National Institute for Health Research, based in London. Pfizer Inc. , which sells a version under the brand name Cyklokapron , provided the tranexamic acid from its plant in Sandwich, England. Pfizer, the world’s largest pharmaceutical company, is based in New York. The researchers asked the World Health Organization , based in Geneva, to categorize the drug an essential medicine, on a shopping list many countries use to determine which products to purchase, Roberts said. The product costs about 3 pounds ($4.43) a dose, with one given as an immediate injection and the second delivered intravenously over an eight-hour period. In the study, 14.5 percent of patients given tranexamic acid died within four weeks of treatment, compared with 16 percent for placebo. About 4.9 percent given the drug died from bleeding, compared with 5.7 percent for placebo. To contact the reporter on this story: Michelle Fay Cortez in London at mcortez@bloomberg.net

Read the full article →

Penn State Drilling Study Questioned Over Industry Tie

June 14, 2010

STATE COLLEGE, Pa. — A Penn State study that paints a rosy forecast on the economic potential of natural gas drilling has been greeted with skepticism from a citizens’ group and a think tank that favors a severance tax largely because the research was funded by an industry group. The Marcellus Shale Coalition will pay more than $50,000 for the study released last month co-authored in part by researchers at Penn State’s College of Earth and Mineral Sciences, the university said. The industry group, in a release on its website, has boasted that among key findings are that “safe and steady development of clean-burning natural gas” in Pennsylvania had the potential to create 212,000 new jobs over the next decade, along with thousands already created. The study also said gas drilling-related activities could create more than $1.8 billion in state and local tax revenues over the next 18 months. Skeptics are wary of results, especially at a time when lawmakers are weighing the merits of installing a severance tax on natural gas extracted from the rich reserve that lies deep underneath most of Pennsylvania. The study was an update of a report last summer from the same researchers, and the Marcellus Shale Coalition paid more than $43,000 for that work. The cover page of the study includes the Penn State name and logo. The second page notes the industry group paid for the study, and includes a disclaimer that opinions and conclusions “are those of the authors and not necessarily those of” the university or the coalition. “What they are doing is distorting the discussion in Pennsylvania,” Jon Bogle, a member of the Responsible Drilling Alliance, said in a phone interview, “because they’ve been able to use Penn State as an authority in what they say.” A separate study by the school in 2008 set off the current wave of public interest in the potential of natural gas drilling and burnished the school’s reputation as a go-to source for industry, lawmakers and citizens. Bogle, in a letter for his Williamsport-based citizens group, asked university president Graham Spanier to “publicly disavow” the recent research because of what he called “greatly exaggerated” results. The group’s letter also makes reference to questions about the research from the liberal-learning Pennsylvania Budget and Policy Center, which favors a natural gas severance tax to help fund drilling-related environmental and local costs, as well as education and health care. Michael Wood, research director for the Harrisburg-based center, said the issue is not so much with funding behind the study, as much as methods used by researchers. As an example, the center has noted that the U.S. Bureau of Labor Statistics estimated there were more than 10,000 people directly employed by the industry in Pennsylvania. A report last year from the Marcellus Shale Education & Training Center, at the Pennsylvania College of Technology in Williamsport – which is also affiliated with Penn State – estimated the number of full-time natural gas-related jobs in north-central Pennsylvania could more than double to between 3,200 and 5,400 positions by 2013, depending on the success of wells. A study earlier this year from the state’s Center for Workforce Information & Analysis estimated gas drilling jobs could grow 55 percent from 2006 to 2016 to more than 12,400 positions statewide. “This is great. … These are good paying jobs, but a lot different than the 200,000 jobs,” Wood said. State Rep. David Levdansky, D-Allegheny, who favors a severance tax and a moratorium on leasing public land for gas drilling, said he was disappointed his alma mater “has chosen to serve as a facade for an industry-sponsored project … It doesn’t meet the rigorous standards of good academic research as far as I’m concerned.” But it was not unusual for such technical or economic impact studies to be funded by industry, said one of the study’s authors, University of Wyoming energy economics professor Tim Considine, who taught at Penn State until 2008. Considine said while their work may serve as a lightning rod for a sensitive topic, “the methods we use are standard … our analysis can stand up to any sort of scrutiny.” The university has taken no position on the findings or recommendations. “At the end of the day our faculty try to stay out of the politics and just focus on the science,” Bill Mahon, vice president of university relations, said Monday. “Penn State is doing more than $765 million in annual research and the claim that we would jeopardize a stellar international research reputation over a small research project is a pretty big stretch,” he said.

Read the full article →

Swaps Desk Compromise for Two-Year Phase-In Considered by Senator Lincoln

June 14, 2010

By Phil Mattingly June 14 (Bloomberg) — Senator Blanche Lincoln is considering compromise language to her derivatives proposal that would phase in over two years a requirement that commercial banks push out their swaps trading desks to subsidiaries. The proposal also would allow the Federal Reserve to provide system-wide emergency assistance to swaps dealers, according to a draft of the compromise obtained by Bloomberg News and confirmed by Lincoln’s office today. The changes are aimed at clarifying questions about the original language and do not pull back from the purpose of the measure, which is to separate commercial banking from derivatives trading, Courtney Rowe, Lincoln’s spokeswoman, said today in an e-mailed statement. The plan “is a strong provision that will protect depositors and get banks back to the business of banking,” Rowe said. “These clarifications will clear up any questions that exist about the intent of the provision without compromising the legislation.” Under the proposed new language, during the phase-in federal banking agencies would have two years to determine the impact of the measure on mortgage lending, small business lending, jobs and capital formation. The proposal does not provide for any action after the study. The revised language being considered by Lincoln would clarify that banks with access to Federal Deposit Insurance Corp. deposit guarantees and the Federal Reserve’s discount lending window would be allowed to hold a separately capitalized swap dealer in an affiliate of the bank holding company . Reconciling the Bills The derivatives language is one part of the larger financial regulatory overhaul being completed this month by House and Senate negotiators, who will continue to meet this week to reconcile their bills. Congressional Democrats said they expect to have legislation ready for President Barack Obama’s signature by July 4. The proposal remains in its early stages and has not been presented to lawmakers, according to a Senate aide. Negotiators are currently scheduled to take up the derivatives language in the final days of the conference committee, the aide said, declining to be identified because the talks aren’t public. Lincoln, an Arkansas Democrat who is chairman of the Senate Agriculture Committee , in April proposed separating swaps trading from commercial banking. She has advocated for the rule in the face of opposition from federal regulators, lawmakers and banks. Dimon Lobbying The banking industry focused much of its lobbying efforts on removing the provision, including personal lobbying of lawmakers by JPMorgan Chase & Co. Chief Executive Officer Jamie Dimon . Banking officials and regulators including Fed Chairman Ben Bernanke said the original proposal could introduce more risk into the system by eliminating a primary hedging mechanism and could restrict bank capital at a time of economic stress. Derivatives, such as stock options, are financial instruments based on the value of another security or benchmark. Some instruments, including contracts that insured mortgage- backed bonds, have been blamed for fueling a financial crisis that led to the worst recession since the Great Depression. Consumer advocates and labor groups — many of the same people who opposed Lincoln in the primary election battle she won last week — have supported the provision from its inception. Lincoln has picked up other high profile support in recent days, including from Federal Reserve Bank of Dallas President Richard Fisher and Thomas Hoenig , the president of the Federal Reserve Bank of Kansas City. To contact the reporter on this story: Phil Mattingly in Washington at pmattingly@bloomberg.net .

Read the full article →

Micromet’s Search-and-Destroy Cancer Missiles Lure Boehringer, Sanofi

June 14, 2010

By Ellen Gibson June 14 (Bloomberg) — Micromet Inc. , a 17-year-old biotechnology company with no medicines on the market, is attracting attention from product-hungry drugmakers. The lure: a technology for fighting cancer without using toxic chemicals. What Micromet has developed is a way to activate T-cells , the elite troops of the immune system, to attack malignancies, including a rare leukemia that strikes children. It has signed partnerships with five of Europe’s largest drug companies: Bayer AG , Sanofi-Aventis SA , AstraZeneca Plc , Merck KGaA and Boehringer Ingelheim GmbH . For years, companies like Micromet have struggled to perfect so-called immunotherapies that mobilize the body’s natural defenses against cancer. At the European Hematology Association ’s meeting in Barcelona on Saturday, Micromet announced that its leukemia treatment led to remission in almost four-fifths of patients in a trial. “With Micromet’s technology, you can give any T-cell the ability to recognize and kill the tumor,” said Michael Morse, an associate professor of medicine and tumor immunology specialist at Duke University School of Medicine in Durham, North Carolina. Although the technology is not fully tested, “there’s every reason to believe that this could work.” The company’s most-advanced drug, blinatumomab, is derived from a common immune-system protein called an antibody that its scientists refashioned to carry out an unnatural task. One end of the protein attracts T cells; the other is engineered to latch onto specific types of cancer cells. Replenishing Armies When batches of these proteins, called BiTEs, for bispecific T-cell engager, are released into the bloodstream, they not only summon the immune cells to attack the cancer, they also stimulate the body to produce more of the cells, thus replenishing its armies. “We’re leveraging the most potent arm of the patient’s immune system and directing it onto the tumor,” said Micromet chief executive officer Christian Itin in an interview. Immunotherapies got a boost on April 29 when the U.S. Food and Drug Administration approved Dendreon Corp. ’s first-of-its- kind cancer vaccine for prostate tumors. The day of its approval, Dendreon’s stock soared as much as 38 percent, and the Nasdaq Biotech Index had its biggest one-day rise in six months. It was a “landmark approval” that gave “positive momentum to the whole biotech space,” said Joseph Pantginis , an analyst at Roth Capital Partners LLC in Newport Beach, CA. Changing Mindset Like Micromet’s drug, Provenge primes the patient’s natural immune system. To make the vaccine, doctors extract white blood cells from a prostate-cancer patient, mix them with vaccine components and inject the combination back into the bloodstream. Provenge “opens a door and changes people’s mindset” about the immunotherapy approach, said Jeffrey Crawford , chief of medical oncology at Duke. The disease blinatumomab is designed to treat, acute lymphocytic leukemia or ALL, isn’t common, but it is a high priority for some doctors. One reason is that two-thirds of the 5,400 new cases in the U.S. each year are children, many of whom only survive with painful chemotherapy that continues for years. In adults the disease is harder to treat than in children; only 30 percent to 40 percent are cured with conventional chemotherapy. At the Barcelona hematology meeting, Micromet showed that blinatumomab can induce complete remission in patients who still had residual leukemia cells after multiple rounds of chemotherapy. About 80 percent of patients who stayed in the study were relapse-free at a median follow-up of 11 months. Killing Leukemia “With older patients, it’s very difficult to rout out the last bit of leukemia,” said Peter Marks , director of leukemia services at Yale-New Haven Hospital. Immunologic methods such as Micromet’s “can be very powerful,” he said. “A treatment that could specifically kill leukemia without causing toxicity would certainly be in demand,” he said. Micromet will begin the last phase of testing required for European approval of blinatumomab this June. Edward Tenthoff , an analyst with Piper Jaffray & Co. in New York, said it could be cleared for use in the U.S. by 2012, and within five years could see $1 billion in annual sales. “There have been no improvements in ALL treatment in three decades,” said Mark Reisenauer , Micromet’s chief commercial officer. “The only comparably underserved disease is melanoma.” Riddled With Cancer Libby Johns is the kind of patient who inspires cancer researchers to try harder. She was diagnosed with ALL in June 2009, a month after her second birthday. When her parents noticed bruising all over her legs, they brought her to the hospital, where doctors found that 90 percent of her bone marrow was riddled with cancer cells. Now three years old, Libby has had blood transfusions and continuous chemotherapy at the Hospital for Sick Children in Toronto, said her mother, Megan. The girl takes pills every day, has intravenous treatments once a month, and shots in the spine once every three months. This cycle, known as the “ maintenance ” phase of treatment, lasts 20 months. Libby must continue the regimen until August of next year. In the course of treatment, Libby’s hair has fallen out three times, and Megan says it’s a struggle to keep the girl’s weight up. Fevers and low blood sugar have put her in and out of the hospital, and when she’s home, the drugs can leave her lethargic. “Some days she doesn’t have the energy to do much,” her mother said. “We just stay home, watch movies, have picnics in the house. I try to let her lead as normal a life as possible.” Few Options While Libby is responding well to treatment, few options are available to children who are not cured with chemotherapy. For adults, who have a high relapse rate, an ineffective procedure called stem cell transplant is the only other line of defense, according to Yale’s Marks. Proven drugs are “very much needed,” he said. Each of Micromet’s partnerships with large drugmakers is aimed at a different, hard-to-treat cancer. The collaboration with Boehringer, announced May 5, will take aim at multiple myeloma , a deadly disease that starts in the bone marrow and often fails to respond to chemotherapy. Pantginis said drugmakers’ interest in the startup goes beyond a desire to license the small company’s drugs. They’re eyeing Micromet’s platform as a way to boost the effectiveness of cancer drugs they already sell, and also to extend the patent protection on those products, he said. If the companies can retool their older drugs using BiTE technology, they can stave off competition from generics in the future. Lab-Grown Proteins The concept of immunotherapy took a long time to bear fruit. In the early 1970s scientists started developing lab- grown proteins called monoclonal antibodies , designed either to block tumor growth or make tumors visible to other immune-system cells. They do this by homing in on specific molecules or “targets” on the surface of cancer cells. The first commercial success came in 1997, when Genentech Inc. and Biogen Idec Inc. launched Rituxan, a drug for non- Hodgkin’s lymphoma. This was followed by best-selling drugs led by Roche Holding AG ’s colon cancer drug Avastin, with almost $6 billion in global sales last year. While these drugs are a big business for companies, most have shortcomings as medicines, said Steven Rosenberg , chief of surgery at the National Cancer Institute in Bethesda, Maryland. “We need to do better than prolonging survival by months,” Rosenberg said. Most of these drugs target just one of multiple drivers of tumor growth. In just a matter of months, tumors in many patients grow resistant to the drugs. Second Generation Scientists at Micromet and other biotech companies said that second-generation antibodies of the sort they are testing will be more effective. Companies like Bothell, Washington-based Seattle Genetics Inc. and Waltham, Massachusetts-based Immunogen Inc. employ what’s known as the “payload” technique. The idea is to link a targeted antibody to a toxic drug that is unleashed once the medicine enters the tumor. One of these experimental drugs, T-DM1 for breast cancer, joins Roche’s best-selling Herceptin to a cancer-killing toxin using Immunogen’s technology and could be approved next year. “The industry understands the limitations of traditional antibodies,” said Micromet CEO Itin. “We’re starting to see very interesting clinical candidates to enhance the activity of antibodies. We’re seeing an evolution.” To contact the reporters on this story: Ellen Gibson in New York at egibson9@bloomberg.net ;

Read the full article →

U.S. Wants BP to Set Up Account for Oil-Spill Damages

June 13, 2010

By Susan Decker and Mark Chediak June 13 (Bloomberg) — President Barack Obama wants BP Plc to set up an escrow account to pay damages claims related to its oil spill and the Coast Guard wants more capacity to contain the leak, the worst environmental disaster in U.S. history. “We want to make sure the money is escrowed for the businesses and want to make sure the money is independently administered so it’s not slow-walked,” White House adviser David Axelrod said today on NBC’s “Meet the Press.” The U.S. Coast Guard gave the company until tomorrow to find more capacity to capture the leak in the Gulf of Mexico. Jon Pack, a BP spokesman, said the company will respond in a “timely manner.” BP’s board meets tomorrow to discuss whether to reduce or defer its second-quarter dividend. “The board will be looking at a number of options when it meets,” Sheila Williams , a spokeswoman for BP, said after Axelrod spoke. “No decision is expected this week.” Obama will address the nation at 8 p.m. on June 15, after he returns from a two-day visit to Alabama, Mississippi and Florida, said Ben LaBolt , White House spokesman. The president is scheduled to meet June 16 at the White House with BP’s chairman, Carl-Henric Svanberg , and other company officials. BP Chief Executive Officer Tony Hayward is also expected to attend, Coast Guard Admiral Thad Allen said today. ‘Substantial’ Reserve Account Establishing the reserve account will be a subject for “discussion,” Axelrod said. “But it has to be substantial. BP has the resources to meet the claims and we’re going to make sure they do.” Allen said the escrow account should be administered by “an independent third party,” which would make sure that the response to claims “happens quicker.” “We’ve been very concerned about the claims process,” he said today on CBS’s “Face the Nation” program. “This is not a core function of an oil-producing company.” He said he hopes for an answer from BP regarding the capacity increase later today. The cleanup costs and legal liabilities resulting from the leak may reach $37 billion, according to Credit Suisse Group AG. Flow Estimates Doubled Scientists and researchers doubled their estimates of the spill’s size on June 10, and BP’s efforts don’t “provide the needed collection capacity consistent with the revised flow estimates,” said Rear Admiral James A. Watson, the federal on- scene coordinator, in a letter dated June 11. It was sent to Doug Suttles , BP’s chief operating officer for exploration and production, and was released yesterday. BP plans to almost triple its capacity to capture oil from its leaking well to as much as 50,000 barrels a day by mid-July, the Coast Guard said June 11. The plan calls for two pairs of production ships and shuttle tankers to replace a cluster of vessels at the site, Allen, the government’s national incident commander for the spill, said June 11 at a press conference in Washington. BP collected about 7,720 barrels of oil and flared 16.9 million cubic feet of gas from midnight to noon today, according to the company’s website . Flow Study The well was releasing 20,000 barrels to 40,000 barrels a day, twice as much as previously estimated, before BP cut away a kinked pipe on June 3, U.S. government scientists and independent researchers reported June 10. They are still studying the current leak rate. Based on government estimates, the drillship isn’t capturing as much of the spill as BP predicted earlier this month. In a June 4 interview with CBS, Suttles said the system would be capable of capturing as much as 90 percent of the flow. The additional ships planned next month will give BP backup pumping ability in the event that one of the vessels can’t be used, Allen said. BP, at the request of the government’s flow- rate group, will install pressure sensors today on the well to help determine the spill rate, said Mark Proegler, a company spokesman. In its application for the well, BP told the government it was prepared for a worst-case oil spill of 250,000 barrels a day. U.K. Prime Minister David Cameron and President Obama talked yesterday and Cameron expressed his “sadness” at the “human and environmental catastrophe” caused by the spill. “The president and prime minister agreed that BP should continue — as they have pledged — to work intensively to ensure that all sensible and reasonable steps are taken as rapidly as practicable to deal with the consequences of this catastrophe,” Cameron’s office in London said in an e-mailed statement. Pensacola Prepares In the Florida panhandle, the city of Pensacola began taking additional steps to protect its marshes and inlets from oil creeping closer to the coast. A plume of oil was detected three miles (4.8 kilometers) south of Pensacola Pass, and another larger plume was seen nine miles (14.5 kilometers) south of the pass, according to a statement on a Florida emergency response website. In Louisiana, Attorney General James Caldwell said his petition for an investigation against BP was granted by a state judge, giving authorization to gather information as part of the state’s probe into the causes of the spill. “The petition alleges that BP has failed to cooperate and share important information with the state,” the Louisiana Department of Justice said in an e-mailed statement today. The spill began after the drilling rig Deepwater Horizon sank April 22, following a blowout of BP’s well that killed 11 of its crew. It has closed as much as 37 percent of the Gulf of Mexico to fishing, cut offshore drilling in the nation by half, polluted 140 miles (225 kilometers) of shoreline from Louisiana to Florida, and cost BP more than $1.43 billion. To contact the reporters on this story: Susan Decker in Washington at sdecker1@bloomberg.net ; Mark Chediak in San Francisco at mchediak@bloomberg.net .

Read the full article →

Novartis Drug Backed by Panel as First Pill to Treat Multiple Sclerosis

June 10, 2010

By Catherine Larkin June 10 (Bloomberg) — Novartis AG won a U.S. panel’s backing to introduce the first pill to treat multiple sclerosis as an alternative to injectable drugs led by Biogen Idec Inc. ’s Avonex and Teva Pharmaceutical Industries Ltd. ’s Copaxone. Novartis’s Gilenia should be “generally recommended” as an initial treatment for MS, not just when other drugs fail, outside advisers to the Food and Drug Administration said in a 21-3 vote today in Silver Spring, Maryland. The panel voted unanimously in favor of the pill’s safety and effectiveness, while saying a lower dose should be tested after approval. The Swiss drugmaker has been in a race with Merck KGaA to sell the first pill to delay progression of MS. The neurological disease affects 2.5 million people worldwide, many of whom have trouble sticking with current therapies because they’re difficult to use or have side effects, according to the National Multiple Sclerosis Society , a New York-based patient group. “This is an enormously effective drug,” said Cynthia Sitcov, the panel’s patient representative. “I hope the agency approves it at the current dose.” The panel voted 20-5 in favor of a new study testing a 0.25 milligram Gilenia pill once a day, which the FDA suggested may be “much safer” than the 0.5 milligram proposed daily dose, which was linked to heart, lung and liver risks and infections in studies. The panel voted unanimously that the study can wait until after the drug is on the market. Novartis said testing a lower dose would take 2,000 patients and five to six years. Shares Rise American depositary receipts of Novartis, each representing one ordinary share, rose $1.52, or 3.3 percent, to $47.45 at 4 p.m. in New York Stock Exchange composite trading . The Basel, Switzerland-based company’s ADRs have declined 13 percent so far this year in New York trading. The FDA usually follows its panels’ recommendations, though it isn’t required to do so. The agency is scheduled to decide whether to approve Gilenia by September. The review, initially set for six months, was delayed three months when Novartis said May 25 that the FDA requested additional analysis of current data. The advisers also recommended that the first dose of the drug be taken under a doctor’s supervision to identify heart rhythm changes linked to starting treatment and suggested that additional testing may be needed to monitor potential eye and lung risks. Les Funtleyder , a health-care strategist at Miller Tabak & Co. in New York, said before the meeting that he expected the drug to become a first-choice option for doctors, also called first-line therapy, with peak sales topping $1 billion a year. ‘Big Advance’ “This will be used in first line eventually,” he said yesterday in a telephone interview. “It’s such a big advance to go to oral from injectable.” Merck, of Darmstadt, Germany, said this week that it had resubmitted its application to sell cladribine tablets as a treatment for MS. The FDA initially rejected Merck’s submission in November, saying it was incomplete. Multiple sclerosis causes the body to attack nerve cells through the immune system. Gilenia and cladribine blunt the attack by targeting white blood cells that harm the protective coating of nerve cells. Cladribine was approved more than a decade ago to fight leukemia. Mitsubishi Tanabe Pharma Corp. , of Osaka, sold rights to Gilenia to Novartis in 1997 and will help the company develop the drug in Japan. Biogen Idec said older treatments such as its Avonex and Tysabri shouldn’t be scrapped if Gilenia, chemically known as fingolimod, is cleared for sale. “While there is a desire among the MS community for the convenience of an oral treatment, it is important for patients and physicians to consider efficacy, safety and long-term experience before choosing any therapy,” the Cambridge, Massachusetts-based company said today in an e-mailed statement. “The safety profile of fingolimod has yet to be established in a larger number of patients in the real-world setting.” To contact the reporter on this story: Catherine Larkin in Silver Spring, Maryland, at clarkin4@bloomberg.net .

Read the full article →

Manhattan Drug Costs Outpace Every Other Place in U.S. in Medicare Study

June 9, 2010

By Drew Armstrong June 9 (Bloomberg) — Medicare, the U.S. health program for the elderly and disabled, spends more per patient on medicine in New York City, in Anchorage, Alaska, and in Great Falls, Montana, than anywhere else, a study found. The program pays 60 percent more on each beneficiary for prescription drugs in the most-expensive area, Manhattan, compared with the least costly area, in Hudson, Florida, researchers said today in the New England Journal of Medicine. Studies from the Dartmouth Atlas of Healthcare , in Lebanon, New Hampshire, had shown regional differences in Medicare payouts for doctor visits and hospital care since 1996. The authors of today’s research said their analysis is the first to plumb spending for Medicare’s drug benefit, which took effect in 2006. Doctors in high-cost regions prescribe “both more drugs and more expensive drugs,” wrote the authors, led by Yuting Zhang, an assistant professor of health policy and management at the University of Pittsburgh . The cost in Hudson, an area in Pasco County, near Tampa, was $1,854 in 2007 for each Medicare beneficiary, while the figure in New York City’s Manhattan borough was $2,973. Other low-spending areas include Dubuque, Iowa; and Detroit. There is little connection between Medicare’s drug spending in parts of the country and its outlays on hospital care or doctors, the study found. Low-spending hospital areas weren’t compensating for lost revenue by treating patients with more prescription drugs, according to the analysis. Lawmakers and members of the Obama administration focused on the variation in hospital spending as part of the health-care overhaul signed in March, looking to save money by making the most-expensive parts of the country more like the least expensive. To contact the reporter on this story: Drew Armstrong in Washington at darmstrong17@bloomberg.net .

Read the full article →

Regeneron’s `Uncommon’ $2 Billion Research Surge Mimics Genentech Tactics

June 9, 2010

By Elizabeth Lopatto June 9 (Bloomberg) — Regeneron Pharmaceuticals Inc. reported a successful study result in its new drug for treating gout, the first of three new treatments that may generate at least $2 billion a year in revenue. The medicines — for gout, eye disease and cancer — are in the final phase of testing needed for U.S. marketing approval. The gout drug Arcalyst, subject of the trial results reported today, may help generate $500 million a year in additional revenue , said Joseph Pantginis , an analyst with Roth Capital Partners in New York. Having three therapies in late-stage trials is “pretty uncommon for a stand-alone biotech today,” said Ted Tenthoff , a Piper Jaffray & Co. analyst in New York. The treatments are emerging from Regeneron’s development of a drug discovery technology that may help the 22-year-old company with just one $20 million-a-year product rival Roche Holding AG ’s Genentech Inc. unit, with its 10 products and $9.5 billion in sales, said Chief Executive Officer Len Schleifer in an interview. “We don’t want the company to sink or swim on the back of any one thing, which is why we’re trying to move an army of ideas forward,” said Schleifer, in an interview at Regeneron’s headquarters in Tarrytown, New York. “We’ve modeled ourselves on the companies like Genentech that had a cadre of people and technologies. Painful Flare-Ups A once-weekly dose of 160 mg of Arcalyst cut the recurrence of painful flare-ups of gout by 80 percent, the study reported today showed. The drug didn’t work to reduce pain once the condition began, a second trial found. “This is a micro-example of our macro plan,” Schleifer said in a telephone interview today. “We weren’t 100 percent certain of where the best place to treat in gout was, so we wanted to have multiple opportunities to move things forward.” Regeneron fell 99 cents, or 3.7 percent, to $25.51 at 9:42 a.m. in Nasdaq Stock Market composite trading. The shares had jumped 66 percent in the 12 months before today. The stock could increase to $31.22, according to the average price target of nine analysts surveyed by Bloomberg. Results from five more late-stage trials on the three drugs are expected to be reported within 12 months, Schleifer said. Pantginis, of Roth Capital Partners, gives the treatments a “better than 50-50 chance” of success. If all the studies prove positive, the three products may generate at least $2 billion a year, Pantginis said. Research Failures That will represent a turnaround for a company that has had three research failures since it began in 1988. In March 1994, the company’s shares tumbled 33 percent in a single day after weight loss and flulike symptoms were linked to its experimental drug for amyotrophic lateral sclerosis, also known as Lou Gehrig’s disease . A second Lou Gehrig’s disease drug failed in January 1997, and shares lost about half their value. In March 2003, an obesity treatment failed and, once again, the company’s value was cut in half. “The difference between a small company and a large company is how you fail,” Schleifer said. “In a large company, you bury the program in the middle of the night and no one comes to the funeral. We do it in the middle of the day, and it is front-page news.” Something Different Following the failure of the two Lou Gehrig’s disease drugs, “it was quite clear we needed to do something different,” said P. Roy Vagelos , the chairman of Regeneron’s board . Vagelos, a physician, led research at Whitehouse, New Jersey-based Merck & Co. from 1976 to 1985, and was the drugmaker’s CEO for 10 years after that. After the research failures, management met and decided to focus on development of a technology their scientists had been working on, rather than a single drug, Vagelos said. “We came up with the approach of traps to neutralize molecules that might be involved with the disease processes, an approach I liked,” he said. Chemical “ traps ” work by binding to certain proteins, stopping them from activating cell receptors that spur a reaction. Arcalyst works by binding to interleukin-1 , a protein that can trigger inflammation. Gout, a form of arthritis, occurs when uric acid builds up in the bloodstream, causing a painful swelling of joints in the toes and foot. Eye Disease, Cancer Regeneron scientists used the same concept to create an as- yet unnamed drug that works against the eye disease age-related macular degeneration and the cancer therapy aflibercept. In those cases, the binding process prevents blood vessel growth. Aflibercept is being tested as a first medication for prostate tumors and as a treatment for patients who fail initial therapy for colorectal and lung malignancies. Approval for aflibercept in all three cancer indications would give it “blockbuster potential,” meaning it may sell $1 billion a year or more, according to Roth Capital’s Pantginis. The eye treatment may generate $500 million after regulatory clearance, he said. Michael Yee , an analyst for RBC Capital Partners in San Francisco, said the company gains from having “strong partners” in Paris-based Sanofi-Aventis SA and Bayer AG , of Leverkusen, Germany, to help support drug development. The clinical trial load “is possible only because they have big pharma partners that are funding 50 percent of the studies,” RBC’s Yee, one of three analysts with a hold rating on the company surveyed by Bloomberg, said in a telephone interview. Eight analysts rate the stock a buy. Bayer Collaboration Bayer is collaborating on the eye drug. Regeneron will get all the U.S. sales, and Regeneron and Bayer will share profits outside the U.S., according to an October 2006 agreement. Bayer made an upfront payment of $75 million, and Regeneron may earn up to $245 million in sales milestones. Sanofi owns 18.6 percent of Regeneron’s shares and pays the company $160 million a year to help with its research. Regeneron stands to receive as much as $250 million in payments if the products top $1 billion in revenue outside the U.S. Under the agreement, Sanofi has the option to co-develop each new antibody Regeneron discovers. The profits in the U.S. will be shared equally, and outside the U.S. will be split on a sliding scale, with Sanofi’s share ranging from 65 percent to 55 percent. The partnership began November 2007 and was expanded in November 2009. ‘Excited About Alliance’ “We’re very excited about that alliance,” said Paul Chew , the U.S. chief medical officer for Sanofi. “Sanofi has the resources, and Regeneron has the technology and the know-how. We’ve preserved the strengths of each.” Genentech too gained from its relationship with a partner. Swiss drugmaker Roche owned 56 percent of the South San Francisco, California-based biotechnology company for more than 18 years, until acquiring Genentech last year. Sanofi’s Chew declined to say whether Sanofi might acquire Regeneron in the future. Schleifer said his drive to be like Genentech stops at the point when that company was acquired by its partner. He’s not isn’t interested in being bought, he said. “We’re not building a company to sell a company,” Schleifer said. “We’re building a company to deliver drugs that make a difference and that will deliver value to shareholders. If you really want to capture the innovativeness of a small company, you leave them alone.” Having Sanofi as a partner will help with that goal, Schleifer said. The French drugmaker hasn’t “Sanofized” Regeneron, he said, and he doesn’t believe they’ll try. “The diversified strategy is something we like to see in biotech,” said Mark Monane , a New York-based analyst for Needham & Co., in a telephone interview. “It’s an important year for the company, as we’ll get to open the envelope on the late-stage products.” To contact the reporter on this story: Elizabeth Lopatto in New York at elopatto@bloomberg.net .

Read the full article →

Youth Hockey Injuries Tripled in Body-Checking Study That May Spur Debate

June 8, 2010

By Nicole Ostrow June 8 (Bloomberg) — Eleven-and 12-year-old ice hockey players showed triple the risk of injuries in games that allow body checking, according to a Canadian study that may “add some heat to the temperature of this topic,” said a director with the U.S. governing body for hockey. Body checking occurs in a hockey game when one player slams into another to knock the puck loose from possession. Youth teams in the Canadian province of Alberta, where the practice is allowed starting at age 11, showed triple the risk of severe injuries and concussions compared with those in Quebec province, where it isn’t permitted in players younger than 13, according to the study. Today’s report , published in the Journal of the American Medical Association, may add to the discussion of body checking already planned at the annual meeting of USA Hockey that begins June 10, said Kevin McLaughlin, the group’s senior director for hockey development. A subcommittee of the sports association is considering raising the age to 13 for the introduction of body checking to allow younger players to develop other skills first — not because of injuries, he said. “I’m interested in every kid having a great experience in youth hockey,” McLaughlin said today in a telephone interview. “We don’t want injuries to happen at any age. It is a contact sport. Injuries still do occur even when you don’t have body checking.” Hockey Basics By developing other game skills initially, young players can become proficient at hockey basics before they’re taught how to body check, McLaughlin said. He said he wouldn’t predict how the organization will react to today’s study. Authors of the research said it is one of the first studies to compare the risk of playing in a youth ice hockey league that allows body checking with one that doesn’t. If the practice wasn’t permitted, more than 1,000 injuries and 400 concussions may be prevented among about 8,800 hockey players ages 11 and 12 in one season in Alberta, said lead study author Carolyn Emery . “The two leagues provided an excellent opportunity to study the public health impact of concussion and injury associated with body checking,” said Emery, an associate professor of sports injury prevention at the University of Calgary, in a statement. “The facts speak for themselves.” 900,000 Youth Players About 900,000 children and teenagers play ice hockey through Hockey Canada and USA Hockey, authors of the study wrote. Many leagues in the U.S. introduce body checking at ages 11 and 12. In Canada, body checking is allowed in some leagues for players ages 11 and 12, with the exception of Quebec, which doesn’t permit the practice until ages 13 and 14, according to the authors. In the U.S., the American Academy of Pediatrics recommends that body checking not be allowed in youth hockey until the age of 16. The practice has been associated in previous studies with 45 percent to 86 percent of youth hockey injuries, the authors wrote. McLaughlin said youth hockey players learn a progression of skills that lead up to body checking. About six years ago, USA Hockey offered a nonchecking category for its leagues but few players registered. USA Hockey represents about 99 percent of all youth players in the U.S., McLaughlin said. Fast, Dynamic “We understand the risk related to body checking in the sport,” Paul Carson, director of hockey development for Hockey Canada in Calgary, said today in a telephone interview. “It is the nature of the sport, it’s fast, it’s dynamic.” Hockey Canada represents all youth players who play during the winter months. Hockey Canada offers training programs for coaches on safety for youth players, he said, and there are some leagues in Canada where body checking isn’t allowed. Hockey Canada will be reviewing the study findings, Carson said. In the U.S., about 135,000 children 5 to 18 years old are treated in U.S. hospital emergency rooms every year for sports- related traumatic brain injury, including concussions, according to a 2007 study by the U.S. Centers for Disease Control and Prevention . Researchers in the study followed 74 teams in the Canadian province of Alberta with 1,108 players, and 76 Quebec teams with 1,046 players for a hockey season to compare the injury rates. Over the season there were 209 game-related injuries and 73 concussions in Alberta compared with 70 game-related injuries and 20 concussions in Quebec, the researchers found. Identifying the Cause Most of the injuries in Alberta were the result of body checking, the authors wrote. In Quebec, the majority of the injuries were from incidental game contact, Emery said. The study also showed that overall injuries from intentional contact were higher in Alberta than in Quebec, suggesting that kids who are allowed to body check play hockey more aggressively, she said. Emery said a new study is under way comparing players ages 13 and 14 in Alberta with those in Quebec, and that may shed further light on injuries. “This study in conjunction with the next will have significant implications in the reconsiderations of the age at which body checking is introduced,” Emery said in a June 4 telephone interview. Today’s study was funded in part by the Canadian Institutes of Health Research and the Max Bell Foundation. To contact the reporter on this story: Nicole Ostrow in New York at nostrow1@bloomberg.net .

Read the full article →

Fayyad Crosses Israel With Boycott of Settler Goods From Wine to Scrubpads

June 8, 2010

By Daniel Williams June 8 (Bloomberg) — Palestinian inspectors were on the hunt for goods in West Bank stores made in Israeli settlements, and metal scouring pads with no labeled place of origin caught their attention. “You better find out where these came from,” said one man, who slapped a “No settlement products” sticker on the door of the Riviera Palace Mall Grocery Store in Ramallah. “They might be from them.” The inspectors were conducting a campaign organized by Prime Minister Salam Fayyad , known until a few months ago for trying to prepare Palestinians for statehood through gradual political and economic change. Now he is photographed tossing contraband goods onto bonfires . His strategic shift includes an effort to persuade Palestinians not to work in the Israeli enclaves, which sell $200 million worth of products a year in the West Bank and Gaza, according to the Palestinian Government Media Center, and “stifle” economic development, Fayyad has said. The campaign will continue until Palestinian homes are “empty of settlement goods,” he told reporters May 27 in Ramallah. “He is creating his own nationalist credentials,” said Mahdi Abdul Hadi , director of the Palestinian Academic Society for the Study of International Affairs in Jerusalem. “He is filling an action gap.” Fresh Approach Fayyad’s efforts are a fresh approach to the conflict with Israel, Abdul Hadi said. Appointed prime minister in 2007, Fayyad, 58, hadn’t taken a position on how Palestinians should resist Israel until the boycott. Instead, he focused on stabilizing areas under his control, including developing a police force and central bank. He has also invested $100 million in schools and community centers, according to Ghassan Khatib , director of the Palestinian media center in Ramallah. Yasser Arafat , the leader of the Palestine Liberation Organization who died in 2004, maintained that the olive branch of negotiation could coexist with the weaponry of armed action. Peaceful protest is the better route for Fayyad, a former World Bank economist and Palestinian representative to the International Monetary Fund, Khatib said. “The idea is to promote nonviolent resistance,” he said. Fayyad wasn’t available for an interview, despite repeated requests to his staff. ‘Campaign of Incitement’ Israel sees Fayyad’s strategy differently. The boycott is “part of a continuous planned and budgeted campaign of incitement,” Deputy Foreign Minister Danny Ayalon said May 2. The Yesha Council, which represents some 300,000 Israeli West Bank settlers, has called it “economic terrorism.” Fayyad had to augment his administrative efforts with some form of resistance, partly because his emphasis on government and economic development might imply that Palestinians accept their current situation, said Nasser al-Qudwa, a former Palestinian ambassador to the United Nations and member of the ruling Fatah party. Fayyad is a political independent. Israeli Prime Minister Benjamin Netanyahu “could interpret Fayyad’s institutional building as surrender,” al-Qudwa said. “This is dangerous territory.” U.S. President Barack Obama ’s administration is sponsoring indirect, and so far inconclusive, negotiations between the two sides. Hamas in Gaza Fayyad administers the West Bank and its 2 million Palestinians. The Gaza Strip, home to 1.5 million Palestinians, is ruled by Hamas, an Islamic party and militia that won parliamentary elections in 2006 and drove out Fatah security forces in 2007 in a power struggle. Israel, the U.S. and European Union consider Hamas a terrorist organization. Israel has built about 100 settlements in the West Bank since the late 1960s. Another 100 embryonic settlements, which Israel calls outposts, have sprung up during the past decade. The International Committee of the Red Cross says they breach the Fourth Geneva Convention governing actions on occupied territory, and Obama has said they aren’t legitimate. Israel says settlements don’t fall under the convention because the territory wasn’t recognized as belonging to anyone before the 1967 Middle East war, which Israel won, and therefore isn’t occupied. Private Sector Help Fayyad’s campaign to root out the goods they produce is paid for mostly by Palestinian businesses through the Karama National Fund, a government task force created to enforce the boycott. By enlisting the private sector, Fayyad is challenging the notion that wearing a business suit is incompatible with battling Israel, said Samir Hulileh , chief executive officer of Palestine Development and Investment Ltd. , a West Bank investment firm. “He is trying to make business and resistance compatible,” Hulileh said. Palestinians boycotted some products as part of a 1987-1992 civil uprising designed to pressure Israel into leaving the West Bank and Gaza Strip. The Palestinian Economy Ministry has no data on the effectiveness of Fayyad’s campaign, said Karama director Omar M. Kabha. While Fayyad also wants the 25,000 Palestinian laborers who work in settlements to quit, Kabha said it will be difficult unless the Palestinian economy can provide alternative employment. “As we build our own industries, we hope to employ these workers,” he said. Inspectors began fanning out May 18 in towns across the West Bank, hanging posters showing an accusative finger demanding that Palestinians stop buying settler goods. Fifty settlement companies are listed in a catalogue they take door- to-door, making items ranging from construction material and cookies to bath salts and wine. “I don’t think I have any settler products here,” Riviera Palace owner Sultan Afori said as inspectors scanned his shelves. “If I did, okay, get rid of them. No problem. Throw them away.” To contact the reporter on this story: Daniel Williams in Ramallah at dwilliams41@bloomberg.net .

Read the full article →

Studying Economics In College Can Influence Your Political Affiliation, Fed Study Finds

June 7, 2010

Taking an economics course in college may have swayed your political leanings, according to a new study by the Federal Reserve’s Bank Of New York. In fact, that undergrad Macro class may still be shaping how you view the world. The Fed’s study (hat tip to the New York Times ‘s Economix Blog ) delved into how the content of a person’s education influences their civic behavior, including party affiliation, political donations, and volunteerism. Though the study’s authors acknowledge that students choosing to study economics may already be right-leaning, they found that economics courses are correlated with GOP affiliation: The number of economics courses completed by the graduates of these… schools significantly decreases the likelihood that a person does not join a political party and the likelihood of joining the Democratic party, while the number of economics courses is positively related to the likelihood of joining the Republican party. For example, taking five economics courses is associated with an eight percent decrease in the likelihood of joining the Democratic party and more than a 10 percent higher chance of joining the Republican party. Interestingly, the report reveals that course choices (and not just the level of a person’s education) affects civic behavior and opinions on social issues many years after graduation. For instance, the study found that business majors — which are treated separate from economics majors — are less likely than students with other majors to have voted in the 2000 presidential election or volunteer for a cause, political or otherwise. Those taking economics classes, the study found, were less inclined to favor “regulation or government intervention affecting prices for specific goods and services, including wages and salaries.” The authors surveyed 2,000 graduates who attended one of four large public universities in Indiana, North Carolina, Florida, or Nebraska during the years 1976, 1986, or 1996. Here’s more from the study: “Those who completed more economics courses were more likely to agree that tariffs reduce economic welfare and less likely to think that trade deficits adversely affect the economy. The more economics courses taken the less likely respondents were to believe that government should regulate oil prices, and the more likely they were to believe that the minimum wage increases unemployment. Finally, the more economics courses taken the less likely respondents were to believe that government that the distribution of income should be more equal.” READ the study here: Is Economics Coursework_ or Majoring In Economics_ Associated With Different Civic Behaviors –

Read the full article →

Lilly’s Erbitux Fails in Study to Stop Colon Cancer Before It Has Spread

June 6, 2010

By Tom Randall June 6 (Bloomberg) — Eli Lilly & Co. and Merck KGaA’s Erbitux, approved for advanced colon cancer, failed to slow tumors in a study designed to expand the medicine’s use to patients whose disease is in an earlier stage. Erbitux, used to treat aggressive colorectal tumors that have reached other areas of the body, didn’t help stop the spread when added to chemotherapy, according to a study reported today at the American Society of Clinical Oncology meeting in Chicago. Erbitux added to the side effects of chemotherapy. The finding is the latest of at least three studies that have narrowed the scope of a drug that was the first of its kind for colon cancer when approved in 2004. Last year, Erbitux’s prescribing information was changed to say that patients whose tumors have a mutation to a gene called KRAS –found in about 40 percent of colon cancer cases — aren’t helped by the treatment. “Unfortunately with cancer, things that are hoped to work don’t always end up working,” said Herbert Hurwitz , associate professor of medicine at Duke University Medical Center in Durham, North Carolina, who wasn’t involved in the study. “This was a well-run study that asked a good clean question and got a good clean answer.” Erbitux had sales of about $1.4 billion last year, according to IMS Health, a drug research company. It continues to be a useful drug for patients with tumors that have spread, said Hurwitz, who spoke in a telephone interview. In those patients, Erbitux competes with Roche Holding AG’s Avastin, which has shown similarly poor performance in studies for mid- stage colon cancer that hasn’t spread. Expected to Work “From a market-share perspective, this would have been a big group of new patients and would have distinguished it from” Avastin, Hurwitz said. “Most people would probably have expected this drug to work as well or better” in earlier stages as later stages, he said in a phone interview. The trial involved about 1,800 participants. About half were given Erbitux along with a chemotherapy called Folfox, while 858 patients were given Folfox alone. After a follow-up of 16 months, both groups had a similar number of patients who didn’t show signs of their cancer returning. Patients taking Erbitux were actually slightly less likely to survive, with 82 percent still alive at follow-up compared with 87 percent taking chemotherapy alone. About 147,000 Americans are diagnosed with colon cancer every year, making it one of the most common forms of tumors, according to the National Cancer Institute . Cancer That’s Spread About 25 percent of patients are first identified with so- called metastatic cancer, which means the disease has already spread to multiple areas of the body, said Steven Alberts , lead researcher on today’s study and professor of oncology at the Mayo Clinic College of Medicine in Rochester, Minnesota. Another third of colon cancer patients are diagnosed with stage 3 tumors, meaning the cancer has begun to reach nearby lymph nodes but haven’t yet established themselves in new regions of the body, Alberts said. The Erbitux study was aimed at stage 3 colon cancer patients. “Maybe it didn’t live up to some of the initial hopes or expectations, but at the end of the day it still is an important drug that clearly is benefiting a proportion of patients,” Alberts said in an interview at the conference. “It is a meaningful drug in the metastatic setting; just not in the earlier setting. “The hard part is to figure out why it happened. That’s the focus of our research now,” Alberts said. KRAS Mutation Erbitux is a man-made antibody, a substance naturally produced by the immune system in response to infection. The drug works by latching onto cancerous cells and blocking replication. The flaw in the KRAS gene, which holds the blueprint for part of a messaging system inside the cell, is thought to render Erbitux ineffective. As many as 40 percent of patients with colorectal cancer have the mutation, according to previous research . Among those without the gene mutation, only about a third to half of patients respond to treatment, Alberts said. In September, a study known as the COIN study found that Erbitux failed to improve the outcomes even for its target group of metastatic colon-cancer patients with normal KRAS genes. Researchers are still examining results from that study to determine why they contradicted other studies. Part of the difference may be due to a different type of chemotherapy and lower doses of treatment used in the COIN study, Alberts said. Lilly, based in Indianapolis, and New York-based Bristol Myers market Erbitux in the U.S., while Merck KGaA, of Darmstadt, Germany, sells it elsewhere. It’s approved for use in colorectal as well as head and neck tumors. The European Union in July rejected the drug as a treatment for a form of lung cancer. To contact the reporter on this story: Tom Randall in New York at trandall6@bloomberg.net .

Read the full article →

Lilly’s Erbitux Cancer Drug Fails to Stop Colon Tumors From Spreading

June 6, 2010

By Tom Randall June 6 (Bloomberg) — Eli Lilly & Co. and Merck KGaA’s Erbitux, approved for advanced colon cancer, failed to slow tumors in a study designed to expand the medicine’s use to patients whose disease is in an earlier stage. Erbitux, used to treat aggressive colorectal tumors that have reached other areas of the body, didn’t help stop the spread when added to chemotherapy, according to a study reported today at the American Society of Clinical Oncology meeting in Chicago. Erbitux added to the side effects of chemotherapy. The finding is the latest of at least three studies that have narrowed the scope of a drug that was the first of its kind for colon cancer when approved in 2004. Last year, Erbitux’s prescribing information was changed to say that patients whose tumors have a mutation to a gene called KRAS –found in about 40 percent of colon cancer cases — aren’t helped by the treatment. “Unfortunately with cancer, things that are hoped to work don’t always end up working,” said Herbert Hurwitz , associate professor of medicine at Duke University Medical Center in Durham, North Carolina, who wasn’t involved in the study. “This was a well-run study that asked a good clean question and got a good clean answer.” Erbitux had sales of about $1.4 billion last year, according to IMS Health, a drug research company. It continues to be a useful drug for patients with tumors that have spread, said Hurwitz, who spoke in a telephone interview. In those patients, Erbitux competes with Roche Holding AG’s Avastin, which has shown similarly poor performance in studies for mid- stage colon cancer that hasn’t spread. Expected to Work “From a market-share perspective, this would have been a big group of new patients and would have distinguished it from” Avastin, Hurwitz said. “Most people would probably have expected this drug to work as well or better” in earlier stages as later stages, he said in a phone interview. The trial involved about 1,800 participants. About half were given Erbitux along with a chemotherapy called Folfox, while 858 patients were given Folfox alone. After a follow-up of 16 months, both groups had a similar number of patients who didn’t show signs of their cancer returning. Patients taking Erbitux were actually slightly less likely to survive, with 82 percent still alive at follow-up compared with 87 percent taking chemotherapy alone. About 147,000 Americans are diagnosed with colon cancer every year, making it one of the most common forms of tumors, according to the National Cancer Institute . Cancer That’s Spread About 25 percent of patients are first identified with so- called metastatic cancer, which means the disease has already spread to multiple areas of the body, said Steven Alberts , lead researcher on today’s study and professor of oncology at the Mayo Clinic College of Medicine in Rochester, Minnesota. Another third of colon cancer patients are diagnosed with stage 3 tumors, meaning the cancer has begun to reach nearby lymph nodes but haven’t yet established themselves in new regions of the body, Alberts said. The Erbitux study was aimed at stage 3 colon cancer patients. “Maybe it didn’t live up to some of the initial hopes or expectations, but at the end of the day it still is an important drug that clearly is benefiting a proportion of patients,” Alberts said in an interview at the conference. “It is a meaningful drug in the metastatic setting; just not in the earlier setting. “The hard part is to figure out why it happened. That’s the focus of our research now,” Alberts said. KRAS Mutation Erbitux is a man-made antibody, a substance naturally produced by the immune system in response to infection. The drug works by latching onto cancerous cells and blocking replication. The flaw in the KRAS gene, which holds the blueprint for part of a messaging system inside the cell, is thought to render Erbitux ineffective. As many as 40 percent of patients with colorectal cancer have the mutation, according to previous research . Among those without the gene mutation, only about a third to half of patients respond to treatment, Alberts said. In September, a study known as the COIN study found that Erbitux failed to improve the outcomes even for its target group of metastatic colon-cancer patients with normal KRAS genes. Researchers are still examining results from that study to determine why they contradicted other studies. Part of the difference may be due to a different type of chemotherapy and lower doses of treatment used in the COIN study, Alberts said. Lilly, based in Indianapolis, and New York-based Bristol Myers market Erbitux in the U.S., while Merck KGaA, of Darmstadt, Germany, sells it elsewhere. It’s approved for use in colorectal as well as head and neck tumors. The European Union in July rejected the drug as a treatment for a form of lung cancer. To contact the reporter on this story: Tom Randall in New York at trandall6@bloomberg.net .

Read the full article →

Bristol-Myers Sprycel Drug Beats Gleevec in Leukemia Patients, Study Says

June 5, 2010

By Shannon Pettypiece June 5 (Bloomberg) — Bristol-Myers Squibb Co. ’s cancer pill Sprycel worked better and faster at eliminating leukemia cells than Novartis AG’s Gleevec, the standard treatment for the blood malignancy, a study of newly diagnosed patients found. Bristol-Myers said it plans to use the finding to seek expanded U.S. approval for Sprycel as an initial treatment for the form of blood cancer called chronic myelogenous leukemia or CML. Sprycel is already approved as a second-line option for patients who fail to benefit from Gleevec. The expanded use could more than double sales of Sprycel by 2015 to $900 million, said Tony Butler , an analyst with Barclays. Novartis is also racing to get a next generation leukemia drug, Tasigna, approved as a first-line therapy. Gleevec, Novartis’s second best-selling drug with 2009 sales of $3.9 billion, revolutionized the treatment of CML nine years ago, turning it from a fatal to chronic disease for many patients. Now, the arrival of two new drugs could cut Gleevec’s market share 25 percent in the next five years, Butler said in a report. “Sprycel could become the next frontline drug for CML and could replace Gleevec,” said Hagop Kantarjian , a leukemia specialist at the University of Texas MD Anderson Cancer Center in Houston, who studied the drug. “For anyone who has a new diagnosis, they should consider this new kind of inhibitor as a viable option that could be better.” Results from the Sprycel study were released today at the American Society of Clinical Oncology annual meeting in Chicago. Tasigna cut levels of a protein linked to chronic myeloid leukemia in three times as many patients as those taking Gleevec after 18 months, Basel, Novartis reported yesterday in a statement. Regulatory Decision Due U.S. regulators are due to make a decision this year on whether to clear Tasigna for newly diagnosed patients, Basel, Switzerland-based Novartis said in April. Like Sprycel, Tasigna already is approved for patients who don’t benefit from Gleevec. New York-based Bristol-Myers plans to seek U.S. regulatory approval this year for Sprycel, the company said in March. The study released today focused on Sprycel’s ability to attack cells with a defective chromosome in the bone marrow called the Philadelphia chromosome, named after the city where it was discovered. In CML, which affects about 5,000 people a year in the U.S., the Philadelphia chromosome produces a gene called Bcr-AbL, which leads to the overproduction of white blood cells. Gleevec, Sprycel and Tasigna stop this chain of events. Cell Signal Target Gleevec was the first drug approved that is designed to suppress a cell signal known to cause cancer rather than poison the tumor cells, as with chemotherapy. Before Gleevec became available, CML patients lived an average of three to five years, according to the American Society of Hematology. With new treatments that have become available over the past decade, 95 percent of CML patients live at least five years. “Gleevec is a great drug, you will never hear me say anything negative about Gleevec, but in this trial Sprycel did even better,” said Renzo Canetta , Bristol-Myers’s vice president of oncology clinical research. “We think Sprycel can offer something more.” In the study, 77 percent of patients taking Sprycel had a confirmed complete cytogenetic response, meaning no cells with the Philadelphia chromosome could be found, compared with 66 percent taking Gleevec. An absence of tumor cells is an indicator of longer survival, said Canetta in a telephone interview. The study followed 519 newly diagnosed patients for at least 12 months. Side Effects Patients given Sprycel were more likely to have a loss of platelets and fluid build-up in the lungs while patients taking Gleevec were more likely to have fluid retention under the skin. Patients taking Gleevec were also more likely to have nausea, rash and muscle pain. Doctors will probably need longer-term data on the benefit of Sprycel and Tasigna over Gleevec for 24 to 36 months before they routinely prescribe the newer treatments as a first-line therapy, said Seamus Fernandez , an analyst with Leerink Swann & Co. in a research report. Price may also keep doctors and patients on Gleevec, said Kantarjian. When generic copies of Gleevec enter the market in 2015 it will cause the price to fall from its average wholesale price of $4,340 for a month’s supply. That price difference could sway some patients to try Gleevec first instead of Sprycel, Kantarjian said. The wholesale price of Sprycel is $6,950 at the 100-milligram dose, Bristol-Myers said. Gleevec Still ‘Reassuring’ “I don’t think this is going to be the end of Gleevec,” Kantarjian said in a telephone interview. “The long-term follow up with Gleevec is very reassuring. Gleevec will also become generic in four to five years so the price difference could become significant.” Bristol-Myers also reported data today that showed its experimental skin cancer drug ipilimumab almost doubled the number of patients alive after two years compared with another experimental treatment called gp100, developed by the National Cancer Institute. Bristol-Myers said it hopes to start selling the medicine by the end of 2012. If approved, ipilimumab could generate more than $1 billion in annual sales, analysts said. To contact the reporter responsible for this story: Shannon Pettypiece at spettypiece@bloomberg.net .

Read the full article →

Electric Helmet Slows Brain Tumors Without Chemotherapy’s Side Effects

June 5, 2010

June 5 (Bloomberg) — Doctors treating brain cancer have a limited toolkit. They can cut tumors out with a knife, burn them with radiation or try to poison them with drugs. NovoCure Ltd., a closely held Israeli company, has added a fourth option for hard-to-treat tumors. It’s an array of electrodes resembling a tight-fitting helmet that bathes the cancer in a faint electric field, scrambling the inner workings of the rampaging cells and preventing them from multiplying. The helmet, powered by a 6-pound battery pack, is designed to zap deadly glioblastomas, the malignancy that killed U.S. Senator Ted Kennedy in August 2009. In a study reported today, it helped patients with recurrent tumors live 7.8 months, compared with a median 6.1 months for patients given the best available chemotherapies or Roche AG’s Avastin. The technology is so different from other treatments, it was difficult to convince patients and doctors to try it, said Philip Gutin , primary investigator for the study. “This new data actually shows that it’s effective,” said Gutin, the chair of neurosurgery at Memorial Sloan-Kettering Cancer Center in New York. “People will ask for this now.” The electric fields resonate at a frequency designed to do no harm to healthy brain tissue. In the test, the only side effect was mild scalp irritation, Gutin said. “If it continues to look as good as it does, it will be used in lots of different treatments. There’s no downside to it.” The study, reported at the American Society of Clinical Oncology in Chicago, followed 237 very sick patients whose cancers had returned after prior treatment and whose tumors, on average, were 4 centimeters (1.57 inches) in diameter. Topping Chemotherapy The study was designed to show that patients using the helmet fared significantly better than those taking chemotherapy and Avastin. On this basis, it was a failure. That’s because more than 50 patients either died or dropped out before they completed the first round of treatment, said Eilon Kirson, head of NovoCure’s research and development. When those patients are excluded from both arms of the analysis, the helmet performed better than other treatments, Kirson said. Under either analysis, the trial found the helmet to be at least as good as other approaches, but without the vomiting, fatigue and infections associated with chemotherapy. While shooting electricity through the brain conjures images of Mary Shelley’s “ Frankenstein ,” or the involuntary electroshock therapy in Ken Kesey ’s “ One Flew Over the Cuckoo’s Nest ,” Kirson emphasized that NovoCure’s technology is new. The helmet is the first cancer therapy to use alternating polarities in electric fields as a way to disrupt the cell division process known as mitosis. “Bad Name” “Electricity has gotten a bad name in medicine in the last century or two,” Kirson said in a telephone interview. “People hear ‘electric fields’ and of course they are skeptical. In order to cross that barrier into biology and medicine, we had to start at the end. The end is glioblastoma.” NovoCure, based in Haifa, was started by Yoram Palti, a professor of electrophysiology and biophysics at Technion-Israel Institute of Technology. Early funding came from Bill Doyle , founder of investment firm WFD Ventures and now chairman of NovoCure. Pfizer Inc. and Johnson & Johnson are also investors, according to a NovoCure statement. Early prototypes were cumbersome for patients, weighing about 15 pounds, Kirson said. The current battery pack looks like a white laptop computer that slips into a shoulder bag, and the company plans to shrink the device further. Patients wore NovoCure’s helmet for about 20 hours a day, shaving their heads twice weekly before reapplying the electrode patches. The patients were able to conduct most of their usual routine with the machine and took occasional breaks for athletic or social events. “A Nice Shower” “We have a patient who plays tennis,” Kirson said. “Whenever she replaces her electrodes, she goes and plays tennis for a couple of hours, she has a nice shower, she goes into the sauna, and when she gets out she’ll put it back on and keep going.” Now NovoCure is testing the helmet simultaneously with chemotherapy in early cases of glioblastoma with hope that a combination will enhance the effectiveness of both treatments. NovoCure is using today’s trial to apply for U.S. marketing approval, and the company seeks to begin U.S. sales next year, Kirson said. The helmet is already approved for use in Europe, though health plans there won’t currently pay the $10,000 to $15,000 a month it costs to wear it. NovoCure is testing similar devices for other types of hard-to-treat cancer. The results of a test in 42 lung cancer patients will likely be released at the European Society of Medical Oncology meeting in September, Kirson said. “I must admit that when I first saw this I thought it was complete and utter trash — I’m being that honest about it,” Kirson said. “It’s such a novel technology, you have to show that you are the real thing. The real reason I went into this was because I had worked with Professor Palti, and I believed in him. I thought he was a brilliant man, and I still do.” For Related News and Information: Health stories from the U.S.: TNI US HEA BN Top stories about science: TNI SCIENCE WWTOP Stories by this author: BIO TOM RANDALL Top health stories: HTOP

Read the full article →

Melanoma Drug Unleashing Immune System Seen as Bristol Cancer Breakthrough

May 27, 2010

By Shannon Pettypiece May 27 (Bloomberg) — For more than three decades, scientists have dreamed of unleashing one of nature’s most powerful inventions, the human immune system, to treat cancer. Now, a wave of treatments that activate the immune system to attack tumors is emerging from drug-company laboratories, giving hope of longer life to patients with terminal lung cancer, leukemia, brain tumors and melanoma, Bloomberg Businessweek reports in its May 31 edition. Leading the push is Bristol-Myers Squibb Co. ’s experimental drug for skin cancer, one of dozens of immunotherapies to be spotlighted next week at the American Society of Clinical Oncology meeting. In its late stages, melanoma can be lethal within months, killing more than 65,000 people a year. Bristol- Myers’s drug, called ipilimumab, extended life in its deadly final phase, three small trials have found. If those results stand in data reported at the meeting, the drug may get U.S. regulatory approval as early as next year and may be in doctors’ hands in 2012, the company said in March 4 investor call. “We have hundreds of patients who are still alive after taking this treatment, and that is something unheard of” in advanced-stage melanoma, Renzo Canetta , Bristol-Myers’s vice president of oncology clinical research, said in a telephone interview. In the earlier trials, ipilimumab kept more than one-third of patients alive for at least 18 months, about a year longer than existing treatments for terminal melanoma. The trial to be reported at the cancer meeting tested the drug in 676 patients for five years, according to the study’s description. Bristol-Myers, based in New York, fell 16 cents, or less than 1 percent, to $22.72 in New York Stock Exchange composite trading yesterday. The company gained 14 percent in the past 12 months before today. 130,000 People Yearly Melanoma affects about 130,000 people a year according to the World Health Organization . No new treatment has been approved for the disease in more than a decade and current medicines keep patients with the advanced stage of the disease alive for six to eight months, said Steven O’Day, who tested the drug for Bristol-Myers at the Angeles Clinic and Research Institute in Santa Monica, California. Ipilimumab is central to Bristol-Myers’s plan to bolster its share of the $52 billion cancer-drug market and counter generic competition during the next six years to drugs with more than $11 billion in annual sales. If approved, the drug may have $1 billion in annual sales within five years, said Linda Bannister a health-care analyst at Edward Jones & Co. Success with ipilimumab will be a sign as to whether the company’s strategy of acquiring small biotechnology companies — they bought the drug’s creator Medarex Inc. for $2.4 billion last year — is paying off. Patent Expirations “Bristol faces a large amount of patent expirations and from that perspective ipilimumab is very important, this could be big for them,” said Bannister, who is based in Des Peres, Missouri. A success “will show that Bristol made a really good acquisition with Medarex,” she said. Jedd Wolchok, a skin cancer researcher at Memorial Sloan- Kettering Cancer Center in New York, is a believer. One of the first patients Wolchok treated with the drug in 2004 was a 24-year-old woman who likely had less than a year to live after failing on other treatments. After getting four doses intravenously, her tumors shrunk and eventually disappeared. She has started a family since and sends Wolchok a Christmas card yearly, he said. “We are resetting the balance between the person and the tumor and the tumor no longer has the upper hand,” Wolchok said in a telephone interview. “We have been talking about turning cancer into a chronic disease, and this shows it is possible.” Derived From Mice The Bristol-Myers’s drug is derived from mice that were genetically altered to create a human version of an antibody, a soldier in the immune system army. The antibody is designed “to push the accelerator down” on the system, said O’Day. The drug blocks a protein called CTLA-4, which when working properly keeps the immune system from getting too revved up and attacking the body’s own tissue. Tweaked by scientists at Medarex, the medicine opens the way for the body to release excessive white-blood cells that attack the tumors the way they would another foreign invader, such as a virus. Along with showing signs of aiding skin cancer patients, the drug’s action may also work against tumors of the lung and prostate, said Trevor Polischuk , an analyst with OrbiMed Advisors LLC in New York. ‘A Game Changer’ “This could be a game changer in cancer,” Polischuk said in a telephone interview. While ipilimumab is now one of Bristol-Myers’s most promising drugs in development, it could have died in testing two years ago had researchers not noticed a strange phenomenon among patients who they thought weren’t benefiting. A study released in December 2007 showed that it failed to meet the U.S. Food and Drug Administration’s criteria of benefiting at least 10 percent of melanoma patients. In 2008, when Bristol-Myers had been expecting to file for approval with the FDA, the company said it would delay its application after the agency said the current studies weren’t enough to garner approval. Company researchers, though, kept studying the drug on a hunch it was having a benefit that wasn’t detected in the studies. They noticed an odd trend among some patients whose tumors continued to get larger while they were on the medicine. Once these patients were removed from the study because they weren’t showing a benefit, their tumors unexpectedly began to shrink and the researchers found they were living months and, in some cases, years longer than expected. Bristol-Myers realized that what appeared to be tumor progression was an inflammatory response from the treatment as the white blood cells called T-cells attacked the tumor. Excluded Patients If researchers hadn’t excluded these patients from the data reported to the FDA in 2008, they may have been able to prove the benefit was greater than seen in previous studies, Bristol Myers’s Canetta said. Ipilimumab won’t be the first in the latest family of cancer immunotherapies to show strong success against a cancer. Dendreon’s prostate cancer vaccine Provenge was cleared by the FDA on April 29. That day, Dendreon’s stock rose as much as 38 percent, and the Nasdaq Biotech Index had its biggest rise in six months. Next week, at the American Society of Clinical Oncology meeting, the world’s biggest gathering of cancer doctors, a range of companies will show how their medicines will provoke, redirect, or accelerate the immune system to kill cancer cells. For instance, New York-based Pfizer Inc. , the world’s biggest drugmaker, will present data on a brain tumor vaccine from a study that’s in the second stage of three needed for U.S. regulatory approval. Micromet Technology Micromet Inc. , a Bethesda, Maryland, biotechnology company, will update doctors about a technology it developed that activates T-cells to attack tumors. German drugmaker Merck KGaA and Oxford BioMedica Plc of the U.K. will show how their vaccines work against breast and kidney malignancies. The concept of immunotherapy has taken a long time to bear fruit. In the early 1970s, scientists started developing lab- grown proteins called monoclonal antibodies, designed either to block tumor growth or make tumors visible to other immune-system cells. They do this by homing in on specific molecules or “targets” on the surface of cancer cells. The first success came in 1997, when Genentech Inc. and Biogen Idec Inc. launched Rituxan, a drug for non-Hodgkin’s lymphoma that last year had $5.7 billion in revenue. Drug Shortcomings While these drugs are a big business for companies, most have shortcomings as medicines because they only targeted one of multiple growth drivers pushing the tumors, said Steven Rosenberg , chief of surgery at the National Cancer Institute in Bethesda, Maryland. “We need to do better than prolonging survival by months,” Rosenberg said. Drugs like ipilimumab may be more effective for longer periods of time because they are training the immune system to recognize and attack cancer cells, researchers say. “The hope is that we aren’t just extending, but that we are really curing people with widespread cancer,” said O’Day, the researcher in California “It is a little early to say that, but there is hope.” To contact the reporter responsible for this story: Shannon Pettypiece in New York at spettypiece@bloomberg.net .

Read the full article →

Marie Wilson: One Giant Oil Rig

May 26, 2010

I had never paid too much attention to oil rigs until sitting on a panel with Deborah Myerson of Stanford University. She described research she had conducted with Robin Ely of Harvard that explored how focusing on safety on these dirty dangerous places had allowed men to abandon behaviors traditionally associated with masculinity. They literally made themselves vulnerable for the sake of the survival of all aboard. Ely’s team was studying gender roles, and they focused on how masculinity could be re-shaped by changing the work environment. They chose the oil rigs on the Gulf Coast as their subject, helicoptered out and lived there to see this transformation. What they found was fascinating: men, for the sake of safety and productivity, were encouraged to abandon the bravado, risk taking, and denying failure associated with tough jobs like these and make themselves, “vulnerable.” As a result the riggers shared with their supervisors and co-workers when they weren’t quite up to snuff that day, felt free to admit to mistakes, and asked questions about information they didn’t understand. The results of these experiments were equally astounding. There were 84% fewer accidents and increased productivity that exceeded the company’s benchmarks when men exchanged behaviors traditionally associated with masculinity and competence for more non-heroic traits. And beyond those outcomes, the study’s results showed, “how organizational features might encourage people to resist those stereotypes,” says Ely. I have thought of this so often with reference to the Deep Horizon spill, where, as it turns out, just before the big blow-out, there had been a celebration of seven years with no accidents on this particular oil rig. But as Mike Williams, one of the last crew members to escape from the rig told Scott Pelley in his harrowing account of survival on 60 Minutes a week ago, precursors for the accident had been building for weeks. Williams talked about the pressure that kept building to drill faster as the time table of finishing the job in 21 days expanded to 6 weeks with the accompanying profitability loss. And as safety gave way to time pressure, the most vital piece of equipment, the blow-out preventer, was damaged. When the workers pointed out this system failure, they were told it was “no problem.” He also described the locking of horns between BP executives and Transnational (the company that actually ran the rig). This clash of the 2 corporations in charge of the rig sent a message to the crew that leadership was back, and that the teamwork the crew had displayed, complete with measures and practices that would keep them and the ocean they worked in safe, was over. The end of this tale is now the worst oil spill in history. Eleven men are dead and with it the fish and fowl, and the dreams and livelihood of countless others as the spill continues. I follow this story every day, and I think of the big blow-outs that have happened in the last decade and how bravado has triumphed and the people of this country, and the world, have lost. I think of all the whistle blowers in the financial crises, from those who warned the SEC about Bernard Madoff, to the journalists and economists who harped on creating financial institutions that were the equivalent of a house of cards, blow-out preventers if there ever were any. As the fall-out from financial crisis continues to play out, that speculation has grown to include articles and inquiries about whether if there had been more women leaders in the financial sector, there would have been a crisis of such proportion. I think there’s a good chance women’s blow-out prevention traits might have prevailed And in regard to foreign affairs, I am reminded of Jessica Tuchman Matthew’s proposal for, “aggressive inspections” as an alternative to going to war with Iraq. She asked that every site where there was any hint of weapons be inspected and even destroyed if inspectors weren’t satisfied; a proposal I am told stayed on the table until a week before the invasion. Think of the blow-out prevention that would have been. Women have been socialized to be more risk-smart cooperative, vulnerable and open to admitting our mistakes and failures. We have our own lessons to learn about feminine roles, but one is the collusion we offer by maintaining the status quo that serves to keeping man-ly men behaviors in place. To take the metaphor all the way , our country and our world seem to me like one gigantic oil rig: an increasingly dangerous place where we have developed instrumentalities that should have improved our lives but which, when spun out of control have put us all in danger. Scientific discoveries that allow us to kill each other in massive numbers; financial wizardry whose fall out is causing loss of our jobs and homes; products that produce wastes that clog our rivers and oceans and kill the lands and waters that we are so dependent on. All of this spills out in ways that like the oil on the gulf waters are becoming beyond our capacity to contain. So how, if making safety the issue could so alter behavior on oil rigs, why we aren’t able to do it on the big rigs we live and float across space on? For the sake of the safety of the planet, why can’t we find some way to cooperate across boundaries, to make ourselves vulnerable, to admit mistakes and learn from failures? Man-ly man behavior in men and acquiescence to these behaviors by women will have to be abandoned. If we don’t pay attention to this, we may be one big unplugged event from our demise.

Read the full article →

Global Banks May Need $1.5 Trillion in Capital, State Support, Study Says

May 25, 2010

By Elena Logutenkova May 25 (Bloomberg) — Global banks may have a capital deficit of more than $1.5 trillion by the end of next year and some may require state support, according to a study by Independent Credit View, a Swiss rating company. Allied Irish Banks Plc , Commerzbank AG, Bank of Ireland Plc and Royal Bank of Scotland Group Plc may have the biggest capital deficits by the end of 2011 among the 58 banks examined in the study, Christian Fischer, a partner and banking analyst at Independent Credit View, told journalists in Zurich today. “Without state aid or debt restructuring these banks will hardly be able to raise capital,” Fischer said, forecasting “massive dilution for existing shareholders.” The study compared estimated capital needs for the end of 2011 with capital ratios reported at the end of last year. The analysts took into account the banks’ earnings estimates for this year and next, forecasts for loan and provisions growth as well as an increase in the tangible common equity ratio to 10 percent from the average of 9 percent at the end of December. Dublin-based Allied Irish and Bank of Ireland may need to raise capital equal to 681 percent and 536 percent of their current market values, respectively, Fischer said. The two Irish banks also got the lowest credit ratings in the study from Independent Credit View, of BB- and B+, respectively. “We do have a substantial amount of capital that our financial regulator here in Ireland has requested us to raise,” Alan Kelly, a spokesman for Allied Irish, said by phone. “A substantial portion of that, that yet can’t be determined because we’re only in process, will be raised through the disposal of assets.” Capital Raisings Ireland’s financial regulator, Matthew Elderfield , who took over in January, has told Allied Irish and Bank of Ireland to raise about 10 billion euros ($12.2 billion) by the end of the year to meet new capital requirements and create a buffer against losses as loans turn bad. “The financial regulator has determined how much capital Bank of Ireland needs and we’re currently in the process of finalizing the raising of an amount in excess of that,” spokeswoman Anne Mathews said by phone. “The findings in this report are clearly out of date.” Bank of Ireland is selling new shares as part of a plan to raise 2.9 billion euros, while Allied Irish has said it will sell stakes in banks in Poland and the U.S. as it tries to raise about 7.4 billion euros. Independent Credit View’s study doesn’t take into account the bank’s transfer of loans to the National Asset Management Agency, Bank of Ireland said. Commerzbank, RBS Commerzbank of Frankfurt may see a capital deficit equal to 611 percent of its market value, while for Edinburgh-based RBS that ratio may be 359 percent, according to the study. Commerzbank is also among the banks that may have the biggest potential for rating downgrades, along with Barclays Plc, Banco Santander SA and Italian lenders, Fischer said. Spokespeople for RBS and London-based Barclays declined to comment. Commerzbank declined to comment. A spokesman for Madrid-based Santander, who asked not to be identified in line with company policy, said the study’s conclusion about potential rating downgrades is “mistaken.” Santander is “one of the best capitalized banks in the world with a very low risk profile and that has continued to generate profit and pay dividends through the financial crisis,” he said. Zurich-based Independent Credit View was formed in 2003. In an August 2007 study, the company warned about higher risks on the balance sheets of German Landesbanks, U.K., Icelandic and Spanish lenders than perceived by other rating companies at the time, Fischer said. To contact the reporter on this story: Elena Logutenkova in Zurich at elogutenkova@bloomberg.net

Read the full article →

EBay’s Whitman Hurt in California Governor’s Race by Goldman, Immigration

May 24, 2010

By Michael B. Marois and William Selway May 25 (Bloomberg) — Meg Whitman , the former EBay Inc. executive who’s seeking the Republican nomination to succeed Arnold Schwarzenegger as California’s governor, has seen her lead in polls evaporate over her ties to Goldman Sachs Group Inc. and her stand on illegal immigration. Whitman, 53, has spent $68 million of her own money in the race only to have her support among likely Republican voters plunge 23 points since March in her race with state Insurance Commissioner Steve Poizner , according to a poll by the Public Policy Institute of California released May 19. Poizner, who was paid $1 billion by Qualcomm Inc. for his cell-phone technology company in 2000, has plowed $24 million of his own into the Republican race. “He’s been hitting her pretty hard on two issues in particular, Goldman Sachs and illegal immigration,” said Dan Schnur , a former Republican strategist who heads the Jesse M. Unruh Institute of Politics at the University of Southern California in Los Angeles. “In different ways, both have hurt her greatly with the party’s base. You’d still have to consider her the favorite for the nomination, but it’s no longer a foregone conclusion.” The race narrowed as Poizner stepped up attacks, accusing Whitman of profiting from pornography, supporting Barack Obama ’s immigration amnesty and failing to vote in past elections. Democrats Join At the same time, Democrats poured money into the race, highlighting Whitman’s position as a former director of Goldman Sachs, the world’s most profitable investment bank, and capitalizing on public anger over Wall Street’s role in a recession that sent the state unemployment rate to 12.6 percent. “You’ve basically got the campaign of Steve Poizner and the Democratic Central Committee doing everything they can to prevent Meg Whitman from becoming the nominee,” said Allan Hoffenblum , a former Republican consultant who publishes books on California political races. Democrats “don’t want Meg Whitman to be the nominee,” Hoffenblum said. “They think they can beat Steve Poizner.” From March through May, Whitman’s lead over Poizner slid from 50 percentage points to 9, according to polls of 2,003 adult residents by the nonprofit, nonpartisan Public Policy Institute, based in San Francisco. Whitman, EBay’s former chief executive officer, held a 38 percent to 29 percent advantage over Poizner in a survey taken from May 9 to May 16. That’s down from 61 percent to 11 percent in March. One-third of likely voters remain undecided, the institute found. Whitman’s early lead was a sign of her ability to use her cash to develop name recognition with voters, said Barbara O’Connor, the director of the Institute for the Study of Politics and Media at California State University, Sacramento. Now, she said, Poizner’s “back from the dead.” Advertising Blitz With just two weeks before the election, Poizner and Whitman have intensified advertising aimed at bolstering their conservative credentials. Poizner, 53, who’s made illegal immigration a central issue, seized on Whitman’s statement that she opposes a new law in Arizona that requires local police to determine the immigration status of anyone suspected of being in the country without proper documentation. Poizner also accused Whitman of making money from pornography because she ran EBay at a time when the online auction site developed a porn and sex-paraphernalia business. “That’s Meg Whitman: From Goldman Sachs deals to porn, it’s all about the money,” says a voice in one of Poizner’s television ads . “Meg Whitman — bad judgment, wrong values.” Insurance Commissioner Whitman, a first-time candidate, says Poizner failed to roll back the size of government during his time as state insurance commissioner. She also said he flip-flopped on support of California’s landmark global-warming law that business groups say will push companies and jobs out of the state. Poizner voiced support for the law in 2006, though he now says he supports a ballot measure to suspend it. “We’ve aggressively defined him as a liberal and using his own record against him,” Rob Stutzman , a Whitman adviser. “We’ve been very focused in defining Meg as the fiscal conservative.” Whitman wasn’t available for an interview yesterday, said her press secretary, Sarah Pompei. The Poizner campaign is seeking to capture anti- establishment sentiment to topple Whitman, whose supporters include former Governor Pete Wilson and ex-Vice President Dick Cheney , said Jarrod Agen , a spokesman. ‘Striking Distance’ “We’re in striking distance now,” Agen said. “The last two weeks will really decide this thing.” Agen said Poizer wasn’t available for an interview yesterday. The contest contrasts with the Democratic primary, in which Attorney General Jerry Brown , 72, is running for the governor’s nomination without serious opposition. That’s left Brown, who was governor from 1975 to 1983, unscathed as he heads toward the general election in a state where Democrats overshadow Republicans, 45 percent to 31 percent. As of mid-March, Brown had $14 million on hand for the general election, records show. California’s election battle follows the worst fiscal crisis since the Great Depression, which led Schwarzenegger and lawmakers to raise taxes and slash spending on schools and health care. Schwarzenegger, a Republican, can’t run again because of term limits. Legislators are now struggling to erase a $19 billion budget deficit through June 2011, a gap that threatens to drain California of its cash and has left it with the lowest credit rating among U.S. states. Concern Among Republicans There’s concern in Republican circles — and delight among Democrats — that the primary election may alienate Latino voters and leave either victor tarnished, said Hoffenblum, the former Republican consultant. That could pave the way for Brown’s victory, he said. “For a Republican to win statewide in California it’s always an upset — this is a Democratic seat,” he said. “For a Republican to win, they have to have a superior candidate, a superior campaign, and it has to be adequately financed. You don’t get elected statewide in California by bashing immigrants, illegal or otherwise.” To contact the reporters on this story: Michael Marois in Sacramento, California, at mmarois@bloomberg.net ; William Selway in San Francisco at wselway@bloomberg.net

Read the full article →

JPMorgan Bull Krauss Joins Erlanger in Predicting Stocks Rally Has Legs

May 21, 2010

By Lu Wang May 21 (Bloomberg) — Michael Krauss , the JPMorgan Chase & Co. analyst who correctly predicted the bottom of the 2007-2009 bear market in U.S. stocks , said the rally that has started since then is unlikely to end with the rout this month. His view was shared by Phil Erlanger of Phil Erlanger Research Inc., who said the advance will resume after the bull market experienced its first correction, or decline of at least 10 percent, since March 2009. Erlanger predicted the Dow Jones Industrial Average will rise to its 2007 record next year. “Everybody thinks that we’re going to crash and we’ll make new lows. I think they’re going to be wrong,” Krauss said in a panel sponsored by the Market Technicians Association in New York yesterday evening. “You don’t correct a 13-month trend, if you think it’s the first leg of a large bullish trend.” Technical analysts study charts of trading patterns and prices to predict changes in stocks. The Standard & Poor’s 500 Index has surged as much as 80 percent from a 12-year low after the U.S. economy returned to growth. The benchmark yesterday entered its first correction during the rally, plunging 12 percent from a 19-month high on April 23, after reports cast doubts about the strength of the economic recovery and European leaders struggled to contain the region’s debt crisis. At yesterday’s close of 1,071.59, the S&P 500 was 24 percent below its level 10 years ago, just after the peak of the Internet bubble, and 3 percent above its closing price on the first trading day after the Sept. 11, 2001, terrorism attacks. The benchmark rose 0.9 percent to 1,081.45 as of 11:34 a.m. in New York. ‘Cheap’ Stocks “This is either a depression-like event, or we’re not likely to see stocks so cheap again in our reasonable lifetime,” Erlanger said. “I don’t see it just yet” being a depression. Erlanger based his projection the Dow average may reach its Oct. 9, 2007, record of 14,164.53 on the Fibonacci theory that says stocks tend to recoup all their losses after erasing a 50 percent decline. The Dow average first recovered half its bear- market retreat on Nov. 16. Another bullish indicator he cites is that the Dow Jones Transportation Average held above its 2003 low during the most recent bear-market slump, even as the industrial average sank to a 12-year low. According to Dow Theory, developed by Wall Street Journal co-founder Charles Dow in the 1800s, moves by the industrial average must be “confirmed” by the transportation average to last. Bull Market Sam Stovall , chief investment strategist at Standard & Poor’s, advised investors to stay in stocks because the bull market may have more room to go. Based on his study of the past 60 years of stock-market movements, no bull market lasted fewer than 26 months and on average, one correction took place during the second year of the bull market. The current bull market began in March 2009 . Louise Yamada , managing director of Louise Yamada Technical Research Advisors LLC, said yesterday there are indications that the market may experience bigger losses. “A cyclical bear may take place in 2010. Today may have been the beginning,” Louise Yamada, managing director of Louise Yamada Technical Research Advisors LLC said. “Enough stocks have been damaged in this decline to suggest that those particular stocks should be sold into the rally.” The S&P 500 and the industrial average this week sank below the average during the past 200 days and lost ground at their 50 percent retracement of the 2007-2009 decline. The NYSE Composite Index , which tracks all stocks on the New York Stock Exchange, yesterday dropped below its Feb. 8 low. Krauss, who in November 2008 projected the S&P 500 would sink to 650 and then called for the subsequent rally in March 2009, agreed that more losses may lie ahead, with the S&P 500 dropping to as low as 950. Still, he said the market will take off again in the second half of this year. “We are going to be in correcting process for three to five months,” he said. Investors should “come down to the long side in July and August.” To contact the reporter on this story; Lu Wang in New York at lwang8@bloomberg.net

Read the full article →

Senate Democrats Said to Have Votes to Advance Wall Street Overhaul Bill

May 20, 2010

By Alison Vekshin and Phil Mattingly May 20 (Bloomberg) — Senate Democrats have the 60 votes needed to approve a procedural motion today aimed at moving the financial-regulation bill toward a final vote, according to a leadership aide. A procedural vote on the sweeping overhaul of Wall Street oversight failed yesterday. The Democrats scheduled a second try for 2:30 p.m. today Washington time. They need at least two more yes votes to reach the threshold of 60 required to wind down debate. A leadership aide who spoke on condition of anonymity said those votes appeared to be in hand. Senator Christopher Dodd said yesterday that he was confident “there will be the necessary votes to allow us to have a final vote on the passage of this legislation.” Two Democratic senators who said the bill wasn’t strong enough — Maria Cantwell of Washington and Russell Feingold of Wisconsin — joined Republicans yesterday in blocking the first attempt to advance the bill. Democrats won votes from the two Maine Republicans, Olympia Snowe and Susan Collins . Dodd, the Connecticut Democrat who wrote the regulatory bill, said he expected Senator Arlen Specter , a Pennsylvania Democrat who was absent from yesterday’s vote and lost his bid for his party’s nomination, to support the cloture motion. That would mean Democrats will need to peel off another Republican vote or persuade Cantwell or Feingold to switch. Yesterday’s vote on the cloture motion by Senate Majority Leader Harry Reid of Nevada surprised lawmakers from both parties who expected the move to succeed after two weeks of debate on amendments from both sides of the aisle. When Democrats fell two votes short, Reid switched his vote to no for parliamentary reasons so he could move for reconsideration. The final tally was 57-42. ‘Needs More Work’ The rejection emboldened some Republicans who had argued the bill was being moved too quickly. “I am pleased many of my colleagues from both sides of the aisle agreed the current bill needs more work,” Senator Mike Johanns , a Nebraska Republican, said in a statement. “This bill wreaks havoc on legitimate risk management, ignores ongoing problems with Fannie Mae and Freddie Mac, and creates a massive new bureaucracy that will impair credit on those that had no role in the crisis.” The vote also was a blow to President Barack Obama , who has pressed Congress to approve the financial-rules overhaul he proposed in June. If the Senate bill is approved, it would have to be reconciled with a House plan passed in December before Obama can sign it in into law. Treasury Statement “Action on a comprehensive financial reform is long overdue, and the American people have a right to expect that the Senate will bring its work to a conclusion right away,” Treasury Department spokesman Andrew Williams said yesterday in an e-mailed statement. Cantwell said her vote on cloture was contingent on consideration of an amendment that would bar swaps dealers from trading contracts that have been rejected by a clearinghouse. “There’s lots of amendments I’d like to offer, but this one is so critical to having a clear transparent marketplace that I couldn’t see moving ahead without getting a vote on it,” Cantwell told reporters after the vote. Feingold, in a statement after the vote, said: “We need to eliminate the risk posed to our economy by ‘too-big-to-fail’ financial firms and to reinstate the protective firewalls between Main Street and Wall Street firms.” The collapse of a compromise on derivatives language, one of the remaining contentious issues, was another setback for Democrats yesterday. $615 Trillion The legislation would push most of the $615 trillion in over-the-counter derivatives to be processed, or cleared, with a third party. Regulators would also be required to impose heightened capital requirements on companies with large swaps positions, and limit the number of contracts a single trader can hold. Derivatives are contracts whose value is derived from stocks, bonds, loans, currencies and commodities, or linked to specific events such as changes in interest rates or weather. Dodd also failed to reach a compromise on the derivatives language in the bill, something he aimed to address through an amendment that would have shelved a rule that would force banks including Goldman Sachs Group Inc. and Bank of America Corp. to move their swaps trading desks to subsidiaries. Dodd, chairman of the Senate Banking Committee, decided not to offer an amendment that would have delayed the measure’s implementation pending a study of its effects by a new council of regulators, spokeswoman Kirstin Brost said yesterday. Swaps-Desk Rule The swaps-desk rule was crafted by Senator Blanche Lincoln, an Arkansas Democrat who leads the Agriculture Committee, as part of her larger plan to strengthen derivatives oversight. Losing bets on swaps tied to mortgage-backed securities pushed New York-based insurer American International Group Inc. to the brink of bankruptcy when the U.S. housing market collapsed in 2008. Lincoln, who has said she will fight efforts to strip the swaps-desk provision, got help from colleagues and the banking industry in keeping Dodd’s amendment off the Senate floor. Senate Republicans and the largest Wall Street banks argued that Dodd’s amendment might prove more onerous than Lincoln’s language, given the uncertainty it would cause in the market during the study period. Senators have been debating and amending Dodd’s proposal, aimed at preventing a repeat of the financial crisis that forced the government to extend $700 billion in bailout funds to banks including Citigroup Inc. and Bank of America. Consumer Bureau The regulatory bill would create a consumer financial- protection bureau at the Federal Reserve, overhaul rules for hedge funds and derivatives, and create a mechanism for dissolving failed firms whose collapse would roil the economy. In other action yesterday, the Senate rejected, in a 60-35 vote, a measure offered by Senator Sheldon Whitehouse , a Rhode Island Democrat, that would have forced credit-card issuers to abide by state limits on interest rates. The Senate also approved by voice vote a Snowe amendment that would require the consumer protection bureau to consider the economic impact of its rules on small businesses. To contact the reporters on this story: Alison Vekshin in Washington at avekshin@bloomberg.net . Phil Mattingly in Washington at pmattingly@bloomberg.net .

Read the full article →

Fathers Suffer From Postpartum Depression Just Like Mothers, Study Finds

May 18, 2010

By Nicole Ostrow May 18 (Bloomberg) — Move over, mothers: about 10 percent of dads experience depression before or after their child is born, an analysis of previous research found. A higher rate of depression symptoms, almost 26 percent, was reported for fathers three to six months after their baby’s birth, according to research published today in the Journal of the American Medical Association . That’s greater than the roughly 5 percent of the adult U.S. male population that suffers from depression, according to previous research cited by the study. Much attention has gone to mothers’ postpartum depression that shows overall rates of 10 percent to 30 percent, while less notice has gone to fathers, the study authors said. Today’s report on dads, the first to pull together research from 43 previous studies in 16 countries, shows overall depression symptoms in new and expecting fathers doubles from baseline rates, said lead author James Paulson. “This isn’t something that’s a widely recognized phenomenon,” said Paulson, an associate professor of pediatrics at Eastern Virginia Medical School in Norfolk, in a May 14 telephone interview. “It highlights that as a problem, and a problem that seems to occur before and after birth and across all nations.” Symptoms of depression, including feelings of profound sadness, fatigue and worthlessness, loss of interest and thoughts of death or suicide can occur in mothers and fathers, he said. Postpartum Depression In women, postpartum depression can begin anytime within the first year after childbirth, and the onset is linked to a variety of factors. After childbirth, hormone levels plummet, and changes in blood volume and metabolism can lead to fatigue and mood swings, according to the Mayo Clinic . Emotional triggers caused by lack of sleep and feelings of being overwhelmed may contribute as well as difficulty with breast feeding and a lack of social support. In men, Paulson said, it’s difficult to know what causes the condition during a partner’ s pregnancy and after the baby arrives. The depression may be tied to whether their partner suffers from depression. It may also occur because of changes in perceived role in life, financial stress, isolation from friends and social activities and sleep deprivation, he said. 28,004 People Paulson and co-author Sharnail Bazemore, a research associate at Eastern Virginia, looked at previous studies to determine how often fathers become depressed during their partners’ pregnancies and after the babies arrive. They also reviewed how depression in the men related to depression in mothers. Today’s findings came from an analysis of studies involving 28,004 people from the countries including the U.S., the Netherlands, Spain, Australia and the U.K. The researchers found about 2,900, or 10.4 percent, of the men in the studies suffered from depression either before the baby was born or after. The depression was highest in the three to six months following the baby’s arrival. Paulson said that may be because family leave ends about that time, particularly in the U.S. “Fathers do experience postpartum depression and prenatal depression,” he said. “If they are aware of that, they may be able to catch it early.” The depression rate for pregnant and new moms in the study was about 24 percent, with about 42 percent experiencing postpartum depression from three to six months after the baby’s birth, according to the analysis. Paulson is working on a study looking at depression in moms and dads starting in the third trimester of pregnancy through six months after a baby’s birth to see who develops the illness and what’s going on in the family that may cause depression. To contact the reporter on this story: Nicole Ostrow in New York at nostrow1@bloomberg.net .

Read the full article →

Grant Cardone: No Shortage of Money

May 9, 2010

1 trillion dollars was lost in the stock market yesterday and it didn’t change your life one little bit! This goes to show you just how much money there exist on this planet. 1 trillion dollars was destroyed due to fear, economic reports, bad news, and maybe, some guy on Wall Street with a fat thumb making an incorrect entry. The point is money is not scarce! There are no shortages of it and it is not something to be concerned or worried about. A trillion dollar destruction of wealth and nothing changed for you or your family. It terrified a lot of people but it shouldn’t. Here is the reality, even if the entire economy collapsed tomorrow the fact is we would all be in it together, all equally effected, all shocked by it yet we would all continue on. One of the reasons people have shortages of money is because of their belief in the scarcity of money. You were taught; “don’t waste”, “money doesn’t grow on trees”, “watch your pennies”, “money won’t make you happy”, and on and on. All these sayings, suggested to you, by others that probably had trouble with money themselves, perpetuate a sense of shortage and difficulty around the topic money. Add to that the idea that your parents, mentors, employers and teachers told that you, “you need to go out into the world and make your money.” Even this is a false. It is against the law to ‘make’ money. Money is printed, stored in massive warehouses and distributed into the economy when necessary. Anytime there is a shortage more is printed. Money is created no different than the printing of legal pads, post-its or even toilet paper. You would never say, “oh I have to go make some legal pads.” Money is to be collected, invested and used! Use the legal pad or it has no value. Save the toilet paper and it won’t fulfill its useful purpose. The same with money, understand you don’t make it, go out and collect it, then use it to position yourself to grow your ideas and dreams and advance the goals of your family or company. Quit worrying about money, quit thinking in shortages and start thinking in terms of abundance. Don’t worry about making it’s not your job. Your job, if you would like to control more money, is to go out into the world and get into the flow of it. The bigger the flow you get into and the smarter and more creative you are, the better your chances of succeeding with money. 1) Remember there exist no shortages. 2) You don’t have to make money. 3) Get into the flow of it. 4) Study others that have proven their ability to collect money. If you want to have more money then get your thinking adjusted about the topic and go out into the world and sell your ideas and dreams so and collect as much as you want. And the next time someone says to you, ‘money doesn’t grow on trees”, know that are talking to someone that understands nothing about money. Today’s US dollars are made from cotton fiber paper. When someone says to you “go make some money” remind yourself that money is printed by the Bureau of Engraving and Printing, and, since 1914, have been issued by the Federal Reserve. Now get rid of all your false ideas about money, quit wasting your time on conspiracy theories and go out into the market place and sell your ideas, dreams, products and services and collect all the money you want. Grant Cardone, Author and Sales Expert

Read the full article →

Nokia Shareholders Lose Patience in Third Year Without Response to IPhone

May 6, 2010

By Diana ben-Aaron May 6 (Bloomberg) — Nokia Oyj has had three years to come up with a rival to the iPhone. Investors say that’s long enough. Chief Executive Olli-Pekka Kallasvuo tried to convince shareholders today at the Finnish company’s annual meeting that Nokia, the world’s largest mobile-phone maker, will have new smartphones this year that will “help close the gap” with Apple Inc. , Research In Motion Ltd.’s BlackBerry and devices based on Google Inc.’s Android software. “Patience is running out and people are starting to worry about eroding brand value,” said Max Jul Pedersen , who helps manage $95 billion at Danske Capital in Copenhagen and is considering selling his Nokia shares. “Nokia has very little to show for their big research and development budget.” Nokia, based in Espoo, Finland, spent almost six times as much as Apple on R&D last year, yet has failed to develop a device with the same mass appeal as the multi-application iPhone. The company’s shares have tumbled about 20 percent in the two weeks since it reported first-quarter earnings that missed analysts’ estimates, wiping out 8.2 billion euros ($10.5 billion) in market value. Now 34 billion euros, or $44 billion, the company’s market capitalization compares with Cupertino, California-based Apple’s $230 billion, and is a shadow of its 1999 peak of 203 billion euros, the highest of any European company. Scattered Ownership Nokia came in 43rd in a brand-ranking study released last week by Millward Brown Optimor , tumbling 30 places in a year. It lost 58 percent of its brand value, the biggest plunge in the top 100 brands, according to the study. Nokia fell as much as 1.3 percent to 8.97 euros and was down 0.2 percent as of 4:36 p.m. in Helsinki. Ownership in Finland’s largest company is scattered around the globe. The company had 156,000 shareholders at the end of 2009, with 38 percent of shares owned in the U.S., where investors see few Nokia phones on store shelves alongside Apple and other competitors. In a push to defend market share, Nokia slashed prices and sold cheaper models, sacrificing profit as the average smartphone price fell 18 percent in the last nine months. Even with the price cuts, its share of the global handset market fell almost 2 percentage points in the first quarter to 36.6 percent, International Data Corp. said April 30. Nokia’s sinking fortunes have prompted some investors to call for management changes. Kallasvuo’s Task “If there were new management, depending on who it was, people could be impressed and it could be a positive catalyst,” said Leon Cappaert , who helps manage 360 million euros of investments at KBC Asset Management in Brussels and sold his Nokia shares a few days after the results. Nokia Chairman Jorma Ollila said at the AGM today that while shareholders have reason to be dissatisfied, the board supports the company’s management on its current strategy, which he said will show results this year. Kallasvuo, who over a span of 30 years has held a multitude of posts at Nokia including general counsel and chief financial officer, became CEO in 2006. Nokia’s downward trajectory began on his watch, soon after Apple unveiled the iPhone in 2007. Last month, Kallasvuo, 56 vowed to fight back with products that are “more intuitive, fun and faster.” “We are working hard to reclaim leadership in high-end smartphones and mobile computers,” he said today. “It’s critical that we improve the customer experience with the usability of both our devices and our services.” ‘May Be Too Late’ Nokia on April 27 announced the N8, its first phone using a rewritten software platform designed to improve usability. The touchscreen phone will be shipped in the third quarter. Yesterday, Nokia and Microsoft Corp. released the first software component from their partnership, seeking to challenge RIM, the Canadian maker of BlackBerry handsets. Still, Nokia will have to be swifter and more nimble to keep up with rivals, investors said. Nokia’s annual R&D budget of about $7.7 billion is 14 percent of revenue, compared with Apple’s spending of $1.3 billion, or 3 percent of sales. Nokia’s expenditure also includes figures for its networks division. “The high-end user they’ve lost to the iPhone has signed up for iTunes and put their information on Apple; Nokia won’t get them back or not without an enormous amount of pain,” said Stuart O’Gorman of Henderson Investors Ltd. in Edinburgh, who sold his shares the day Nokia announced first-quarter results. “You have to run so fast to stay still in this market. It may be too late.” Dividend Payout Nokia’s average selling price for all models has plummeted 44 percent in the last five years to 62 euros. Nokia charged, on average, 155 euros in the first quarter for a smartphone, down from 190 euros nine months ago. “Nokia is cutting prices because it’s the only way they can keep market share,” said Francisco Jeronimo , a London-based analyst at IDC. He expects the company’s share of global shipments and profits to decline further, and says Nokia may lose its European market leadership to Samsung Electronics Co. as early as this year. “The best way to leverage Nokia’s strengths is to be a mass producer of cheaper, good quality products, which would rapidly lower their R&D costs,” said Pedersen. One thing Nokia still offers investors is a dividend. The company plans to pay 40 cents per share for 2009, the same as in 2008 even though earnings fell 78 percent. Apple CEO Steve Jobs hasn’t paid a dividend since 1996, preferring to preserve money. Apple had $23 billion in cash and short-term investments as of the end of March compared to Nokia’s $12.4 billion. Analysts question how long Nokia can maintain a dividend of the current size. Listening to Investors Nokia replaced its finance chief last year after posting the first loss since the company began reporting quarterly in 1996. Sales chief Timo Ihamuotila took over from Rick Simonson , who now runs the low-end phone unit. Kallasvuo was selected by previous CEO Ollila . “If they change the CEO or something, that could be a trigger to the stock price performance,” said Niklas Lund , a fund manager at Alandsbanken Asset Management in Helsinki. “That’s not likely. He was handpicked by the chairman and you would have to change them both. Investors don’t really get heard on the board.” To contact the reporter on this story: Diana ben-Aaron in Helsinki at dbenaaron1@bloomberg.net

Read the full article →

Study: Older, Unmarried, Educated Moms On Rise

May 6, 2010

New mothers in the U.S. are increasingly older and better educated than they were two decades ago, according to a study on the state of American motherhood released Thursday by the Pew Research Center. But that doesn’t mean women are waiting for the right moment: The study also found that half of mothers surveyed said parenthood “just happened.” While most women giving birth are doing it within the context of marriage, researchers said a record 41 percent of births were to unmarried women in 2008. That’s up from 28 percent in 1990, according to the study, “The New Demography of American Motherhood.” The trend crossed major racial and ethnic groups. Nearly 14 percent of mothers of newborns were 35 or older two years ago – and only about 10 percent were in their teens. The age trend was reversed in 1990, when teens had a 13 percent share of births. “I think everyone will welcome a decline in births to teens,” said D’Vera Cohn, a senior writer on the study. “It’s notable that the population of teens is larger than it used to be, so there were more who could have become teen mothers.” Today, one in seven babies is born to a mother at least 35 years old. In 1990, one in 11 had a mother in that age group. Most mothers of newborns (54 percent) had at least some college education in 2008, an increase from 41 percent in 1990. Among mothers 35 or older, 71 percent had at least some college education. Improvements in medical care and fertility treatment, along with marriage and childbearing postponed to seek additional education, all factor into the shifts. “The rise in women’s education levels has changed the profile of the typical mother of a newborn baby,” the report said. Cohn added that a lower share of mothers ended their education after high school, “so some of those mothers who would have been high school graduates in 1990 have some college education today.” The report is based on data from the National Center for Health Statistics and the U.S. Census Bureau, along with a telephone survey in April 2009 of about 1,000 parents, likely parents and other adults of both genders. Overall, there were 4.3 million births in the U.S. in 2008, compared with 4.2 million in 1990. The number had risen each year from 2003 to 2007, then dipped in an apparent link to the economic downturn, the researchers said. When American parents are asked why they decided to have a child, most cite “The joy of having children,” the study said. For nearly half of parents, though, an important explanation is: “It wasn’t a decision; it just happened.” Women surveyed were more likely than men to cite “it just happened” as somewhat or very important in their decision to give birth the first time. Stephanie Coontz, director of research and public education for the nonprofit Council on Contemporary Families and a writer who teaches history and family studies at The Evergreen State College in Olympia, Wash., said the rise of single motherhood is significant. “It’s yet another nail in the coffin in the hope that we can solve the challenges facing us today by shoehorning everyone back into marriages,” she said. “One of the big problems with that at this point is very often kids do worse if their mother rushes into a marriage that may be unstable.” Multiple births associated with the trend toward older motherhood were up sharply, including a 70 percent increase in the twin birth rate from 1980 to 2004. “Not only are women in their 30s more likely than younger women to conceive multiples on their own, they also are more likely to undergo fertility treatments, which are linked to births of multiples,” the researchers said.

Read the full article →

Jeff Madrick: A "Modest Proposal" for Capital Market Reform: Close Down Rule 144A

May 5, 2010

This article was co-written by Stephen Diamond. Years ago, it is unlikely deals like Goldman Sachs’ now infamous Abacus would have been sold. The securities laws written in the 1930s demanded more accountability than we have today, not only for public offerings of stocks and bonds, but for private placements like Abacus. Such private placements had to go through a review process before the Securities and Exchange Commission and issuers were held to high standards of disclosure. No longer. Enter Rule 144A . In one simple step the Securities and Exchange Commission could remove a major cause of the recent credit crisis by shutting this rule down. Issued in 1990, the rule was the SEC’s attempt to make it easier for companies to sell securities in so-called “private placements.” Private placements avoid advance SEC review of disclosure about an offering and, more importantly, exempt issuers, as well as their directors, officers, accountants and underwriters from the most effective liability provision in the federal securities laws, Section 11 of the Securities Act of 1933. Section 11 allows investors who are misled to sue those parties for damages. Issuers face “strict liability” under this provision while other parties who help prepare the disclosure escape liability only by following a rigorous due diligence process. Under Rule 144A, an issuer of a mortgage backed security or a note linked to a collateralized debt obligation can be sold initially to an investment bank and then re-sold immediately to so-called “qualified institutional buyers” such as pension funds, banks, insurance companies and mutual funds. The “Abacus” CDO transaction at the heart of the SEC’s charges against Goldman Sachs, for example, was completed using Rule 144A. While appropriate in limited circumstances, such private securities sales have exploded in size and complexity. More than a trillion dollars of such offerings were made in 2006 alone, triple the amount in 2002. The significant losses experienced by even large financial institutions suggest that the original justification for Rule 144A — that large institutions could, in the words of a leading Supreme Court case, “fend for themselves” — no longer holds. In fact, the SEC itself now admits “investors and other participants in the securitization market did not have the necessary tools to be able to fully understand the risk underlying those securities and did not value those securities properly or accurately.” In response, the SEC recently proposed to tweak the disclosure requirements for asset backed securities. But their proposal does not go far enough. The strict liability penalty of Section 11 and the mandatory SEC review process were at the heart of the original design of the securities laws in the New Deal era. They insure that investors in public markets are provided full disclosure of the risks associated with a securities transaction. In the words of Justice William O. Douglas, an SEC Chairman prior to his elevation to the Supreme Court, Section 11 was consciously intended to have an in terrorem effect so severe that those who prepared the offering would be hyper vigilant in disclosing risks to investors fully and clearly. In addition, the review process conducted by the SEC’s Division of Corporate Finance is intensive, rigorous and adversarial with the SEC acting, as Justice Douglas said it should, as “the investor’s advocate.” The Commission’s staff asks tough questions and often pushes the issuer and the underwriters and their counsel to make significant changes to the disclosures in order to make sure these are complete and comprehensible to investors. Now Rule 144A has given rise to a massive parallel private market largely outside of these protective measures. Thus, diligence and disclosure standards can weaken considerably. One academy study found that yields on bonds issued in 144A transactions are higher than those on registered public offerings due to the “lower liquidity, information uncertainty, and weaker legal protection for investors” found in these deals. While some of the anti-fraud remedies of the securities laws still apply in 144A transactions, these have been watered down in recent years by Congressional action and judicial interpretation. In a series of opinions authored first by Justice Powell and then by Justice Kennedy, the Supreme Court has steadily scaled back the scope of the securities laws. Opinions by Justice Kennedy, in particular, limited the impact of anti-fraud protections as well as the ability of investors to sue gatekeepers who play a significant role in preparing offerings. The combination of legislation, judicial opinions and SEC rule-making over the last thirty years laid the ground work for the crisis we are now experiencing. It is time to undo the damage. Putting an end to the unregulated world of Rule 144A offerings would be a great place to start. Cross-posted from New Deal 2.0 .

Read the full article →

Atlanta Fed’s Guynn Warned in 2004 Low Rates Might Fuel Home-Price Surge

May 1, 2010

By Joshua Zumbrun May 1 (Bloomberg) — The president of the Federal Reserve Bank of Atlanta told fellow policy makers in 2004 that the central bank’s low interest rates may be contributing to surging home prices, according to transcripts of their meetings. “The substantial run-up in house prices, which we have followed in Florida and also see in the populous Northeast and West Coast of the United States, may be at least partially attributable to unusually low mortgage rates influenced by our very accommodative policy,” then Atlanta Fed President Jack Guynn told the Federal Open Market Committee on Dec. 14, 2004, according to transcripts released yesterday. Economists including John Taylor of Stanford University, a former Treasury undersecretary, have said that low interest rates under former Fed Chairman Alan Greenspan helped fuel the housing boom and bust that precipitated the recession. Ben S. Bernanke , the current chairman and a Fed governor in 2004, has disagreed, saying in a January speech that the central bank’s policy of maintaining a low target rate shouldn’t be blamed for the housing bubble. “The direct linkages, at least, are weak,” Bernanke said. “House prices began to rise in the late 1990s, and although the most rapid price increases occurred when short-term interest rates were at their lowest levels, the magnitude of house price gains seems too large to be readily explainable by the stance of monetary policy alone.” Home Prices While the Fed held interest rates at 1 percent from June 2003 until June 2004, the rise in home prices accelerated, eventually leading to the crash in valuations that preceded the financial crisis. The annual increase in home prices reached a record 20 percent in July 2004, according to the Standard & Poor’s Case-Shiller 10 City Composite Home Price Index. The index hit a peak in June 2006. Policy makers in June 2004 raised the federal funds target to 1.25 percent from 1 percent, the first of 17 consecutive quarter-point increases over two years, stopping at 5.25 percent. The Fed releases FOMC transcripts after five years. Other policy makers also raised concerns about home prices during meetings in 2004. On Sept. 21, then-Boston Fed President Cathy Minehan said consumers are “willing to take saving rates to record lows in the wake of substantial appreciation in housing prices. Clearly, this could turn around and is a potential source of downside risk.” On Nov. 10, Gary Stern , president of the Minneapolis Fed, reported to the committee on a meeting his bank held partly to look at “a potential bubble in house prices.” ‘Credit Pendulum’ Stern told the FOMC that “a couple of the lenders did say that they thought the credit pendulum had swung too far. They felt that credit conditions had become too easy, and they were anticipating some potential difficulties going forward — presumably in somebody else’s shop!” During 2004, the share of subprime originations in the mortgage market more than doubled. In 2004, 18.5 percent of mortgages were subprime, compared to 7.9 percent in 2003, according to Harvard University’s “State of the Nation’s Housing” report , citing data from Inside Mortgage Finance. Then-Fed Governor Edward Gramlich in May of 2004 said in a speech about “Benefits, Costs and Challenges” of subprime mortgage lending that “while the basic developments in the subprime mortgage market seem positive, the relatively high delinquency rates in the subprime market do raise issues.” Risks of Collapse Greenspan in an Oct. 19, 2004, speech raised the risks of a collapse in home prices, saying “these concerns cannot be readily dismissed.” “Should home prices fall, we would have reason to be concerned about mortgage debt; but measures of household financial stress do not, at least to date, appear overly worrisome,” Greenspan said. In March 2004, Guynn also warned of speculative excess in housing. “A number of folks are expressing growing concern about potential overbuilding and worrisome speculation in the real estate markets, especially in Florida,” Guynn said. “Entire condo projects and upscale residential lots are being pre-sold before any construction, with buyers freely admitting that they have no intention of occupying the units or building on the land but rather are counting on ‘flipping’ the properties — selling them quickly at higher prices,” he said. Guynn, who retired as head of the Atlanta Fed in October 2006, didn’t respond to messages seeking comment. Perplexed by Speculation In June 2004, central bank officials were perplexed by speculation in housing and rising home prices in the course of discussions that resulted in an increase in borrowing costs, according to the transcripts. Stephen Oliner, then Fed associate research director, told the FOMC on June 30, 2004, that the ratio between rents and prices deviated from historical trends and wasn’t explained by “fundamentals,” according to the transcripts. “I don’t want to leave the impression that we think there’s a huge housing bubble,” Oliner said. “We believe a lot of the rise in house prices is rooted in fundamentals. But even after you account for the fundamentals, there’s a part of the increase that is hard to explain.” At the December meeting, Guynn said the home-price boom required a review. “The risks associated with the run-up in house prices probably deserve further study and thought as we decide how to posture policy,” said Guynn. To contact the reporter on this story: Joshua Zumbrun in Washington at jzumbrun@bloomberg.net

Read the full article →

Dendreon Advances the Most in Year After Winning Approval for Cancer Drug

April 29, 2010

By Catherine Larkin April 29 (Bloomberg) — Dendreon Corp. won approval for its first product, a vaccine to fight prostate cancer, after a three-year battle with U.S. regulators. The Food and Drug Administration cleared sales of the medicine, called Provenge, Shelly Burgess, a spokeswoman for the agency, said today in a telephone interview. Dendreon, of Seattle, submitted its application with the FDA in November 2006 and, after winning the backing of an advisory panel in 2007, was required to conduct another study to prove the drug worked. Provenge will be the first medicine to train the body’s immune system to attack cancer cells like a virus. More than 27,000 men die of prostate cancer each year in the U.S., according to American Cancer Society . Provenge may bring in $4.3 billion in annual sales by 2020, according George Farmer , an analyst with Canaccord Adams Inc. in New York. “Demand will be very high given the simplicity and convenience of administration combined with the extremely benign safety profile,” Farmer said in a research report today before the FDA’s decision was announced. Katherine Stueland , a spokeswoman for Dendreon, didn’t immediately return a telephone call for comment. Dendreon gained $5.88, or 15 percent, to $45.50 in Nasdaq Stock Market composite trading before shares were halted. Before today, the shares had gained 51 percent so far this year as investors looked ahead to the FDA decision, scheduled for May 1. Stock Volatility The historic volatility of the stock attracts traders and short sellers who seek short-term profits. Hedge funds own 27 percent of Dendreon shares, according to data compiled by Bloomberg. Provenge helped men whose prostate cancer had spread to other organs live four months longer in the 512-patient study released by the company in April 2009. The company had initially applied for approval based on an earlier study of 127 men that showed the drug improved survival and a second study of 98 men that failed to show a statistically significant benefit. The therapy involves extracting white blood cells from a patient, mixing them with vaccine components and injecting the combination back into the person. It is designed to be given earlier in treatment of the cancer and pose fewer side effects than chemotherapy. The FDA’s refusal to approve the drug in May 2007 based on the original data — even after the agency’s outside advisers voted 13-4 that it was “substantially effective” — sparked protests by patients and threats of a congressional probe. Sales Plans Dendreon Chief Executive Officer Mitchell Gold said Feb. 9 that the company will have three plants to make Provenge by mid- 2011 and 125 sales representatives. Production will be at full capacity within one year of approval, he said. Questions about manufacturing logistics and Dendreon’s ability to meet demand for Provenge have resulted in varying estimates for potential sales of the product. The drug will generate $1.2 billion by 2014, according to the average estimate of four estimates surveyed by Bloomberg. That year, Farmer projected Provenge would cost about $94,000 for each patient treated with a full course of the medicine. Provenge can generate $3.1 billion in 2014, he said. At least a dozen additional products that harness the immune system to battle tumors are in late-stage development and Provenge approval “would be an important validation to the field,” said Janice Reichert , a senior research fellow at the Tufts Center for the Study of Drug Development in Boston. “Provenge will certainly be a pioneer in that area,” Reichert said in an April 21 phone interview. “The experience will definitely inform the clinical development programs of other companies and other products.” The most advanced of these vaccines include Stimuvax from Merck KGaA in Darmstadt, Germany, and Oncothyreon Inc. in Seattle; ipilimumab from Bristol-Myers Squibb Co. in New York; and TroVax from Oxford BioMedica Plc in Oxford, United Kingdom. To contact the reporter on this story: Catherine Larkin in Washington at clarkin4@bloomberg.net .

Read the full article →

Timothy Geithner: Using Education to Cope With a Complex Economy

April 27, 2010

While Americans from Wall Street to Main Street focus on much-needed financial reforms that will set and enforce clear rules across the financial marketplace, we also need to recognize that most Americans don’t have the knowledge and skills they need to make the right financial decisions for themselves and their families. Last year, the FINRA Investor Education Foundation’s National Financial Capability Study , conducted in consultation with the Department of the Treasury, found that too many Americans are giving away their hard-earned dollars to bank and credit card fees. Most don’t maintain a rainy-day fund for emergencies. Few are able to perform basic interest calculations necessary to compare the cost of a loan or to figure out how much to try to save. On just about all measures, the study found young adults are the least money-savvy. In December, the administration announced the National Financial Capability Challenge, a partnership between the Departments of Treasury and Education focused on promoting financial education among high school students and assessing their knowledge of personal finance. The results are in. More than 2,500 teachers and 76,000 students in all 50 states participated in the voluntary exam, which shows interest is strong. But the scores were disappointing. The average student is just squeaking by with 70% correct. Students failed to answer basic questions about credit cards, car insurance, and compound interest. This shows we have a lot of work to do. Luckily we have important models to follow. For example, at Stonewall Jackson High School in Manassas, VA, teacher Terri Carson helps students manage the student-run credit union and includes a financial literacy boot camp in all her classes. She had over 100 students take the Challenge. Over half of them scored in the top 20% nationally; 17 had perfect scores. Those results are commendable, and Carson is working to replicate them. She is hoping to work with her school and the Prince William County School District to make sure that all students demonstrate a basic understanding of personal finance in order to graduate. Today we are recognizing Carson and many teachers and students who participated in the National Financial Capability Challenge, for their commitment to financial education. We hope to see more locally driven efforts to make youth financial education a priority in schools across the country. At the same time, we’ll be doing our part at the federal level. In our schools, we will promote a well-rounded education that includes financial literacy. We will give consumers the information and education they need to make smart financial choices. And we will work to provide all American families with access to the bank accounts they need to manage their daily finances. The agenda is clear. Let’s pass serious financial reform. Let’s promote financial access. And at the same time, let’s make sure that we are providing all Americans — especially our youth — with the financial education they need to succeed in this increasingly complex, fast-moving economy. Their futures — and ours — depend on it. Timothy Geithner is the current U.S. Secretary of the Treasury. Arne Duncan is the current Secretary of Education. And Valerie Jarrett is an Obama White House Senior Advisor.

Read the full article →

Kevin Connor: Obama Needs to Turn His Back on Goldman’s Support

April 23, 2010

In the wake of the historic fraud suit against Goldman Sachs, it was unclear whether the bank would have any presence at President Obama’s financial reform speech yesterday. But CEO Lloyd Blankfein chose to attend, along with his number two, Gary Cohn . Why? The President invited them. Instead of getting a tongue-lashing for their fraudulent ways, the President asked them to join him in the fight for financial reform. If Obama is to be a credible voice for financial reform, and for a just and sustainable economy, he needs to turn his back on Goldman Sachs and other financial behemoths — including hedge funds like John Paulson’s premised on a business model of outright deception and collusion. Symbolic gestures won’t do it. One strategy: he could refuse all future campaign donations from individuals associated with these firms. Goldman Sachs has enormous influence over this White House, in large part because of the role the bank played in helping elect Obama. The fact that Goldman was Obama’s top corporate contributor does not begin to illustrate the central role the bank’s networks played in Obama’s campaign — not just current employees and executives, but, crucially, Goldman alumni. These quiet players have not gotten much attention, but their significance to the Obama campaign cannot be overstated. One of these Obama supporters is former Goldman Sachs executive Richard Perry , now a hedge fund manager. During the 2008 campaign, Perry hosted a pivotal meeting between Obama and Caroline Kennedy. At the time, Hillary Clinton was still in the race; after winning Caroline Kennedy ‘s support, Obama emerged as the chosen candidate of an extremely influential arm of the Democratic Party elite. The New York Post has described this as ” a move some credit with helping Obama score the Democratic nomination over Sen. Hillary Clinton .” Perry’s support is all the more notable for the fact that he and his wife had been Hillary Clinton bundlers. He may have been brought on board by his mentor at Goldman Sachs, Robert Rubin . In addition to working for Rubin, Perry babysat for his children and taught classes with him. Rubin’s fingerprints are all over the Obama campaign: longtime right-hand man Michael Froman , who followed Rubin from the Treasury Department to Citigroup, played a central role in early fundraising efforts, lining up an unrivalled fundraising team of politically-interested financiers in early 2007. Froman was later charged with picking economic appointments for the Obama administration, along with Rubin’s son, Jamie. Then there are people like David Heller , co-head of Goldman’s securities division; Frank Brosens , a hedge fund manager and formerly a Goldman trader under Rubin, and at one point Obama’s pick to oversee TARP; Bruce Heyman , a Goldman managing director in Chicago; Eric Mindich , a hedge fund manager and former Goldman trader under Rubin; Jim Johnson , a Goldman director and chair of the compensation committee — in charge of approving all those exorbitant bonuses. Johnson was Obama’s choice to lead his search for a vice president before his ties to Fannie Mae got him in trouble. All five were Obama bundlers, and all five had strong ties to Goldman Sachs. They raised at least $850,000, and possibly as much as $2.1 million for Obama. That’s more than double the amount given to Obama by current Goldman executives ($1 million), all raised by a handful of people in the Goldman alumni network. You can bet that all of these individuals hold Goldman Sachs near and dear to their hearts. What has all this money won Goldman’s network? One need look no further than White House visitor logs to get an idea of the extent of the bank’s influence over this administration. In a study of the logs earlier this year, citizen analysts at LittleSis.org found that more high-powered visitors to the White House had ties to Goldman Sachs than any other business in the country . We looked for individuals who had attended small group or one-on-one meetings with the President or one of his top advisors, identified them, and analyzed their relationships. Out of a list of 250 visitors, seven current and former Goldman employees had attended such meetings, based on our study of available logs. Morgan Stanley and the New York Times were next with six each. And now one former White House official, Greg Craig , has been hired by Goldman to help it clean up its legal mess. Against this backdrop, Obama’s insistences that he is independent of Goldman Sachs look extremely disingenuous, and rumors that he pressed the SEC to sue Goldman seem far-fetched. Obama’s coziness with Goldman Sachs poses a serious political liability in the months ahead. During Bush’s second year, a wave of corporate crises took down several large corporations, including that reigning symbol of corporate corruption, Enron. Bush took heat for his close ties to “Kenny boy” and his mismanagement of the crises, and his approval ratings began dropping . Businesses like Enron may have put him in the White House, but they also threatened to take down his presidency. The run-up to the Iraq War eventually distracted Americans from this shameful cronyism. Ironically, Enron was just as close with members of the Clinton administration, and its fraud was aided and abetted by Clinton-backed legislation. But Bush took the heat, for good reason: he was the Enron crony in power. And even though Republicans also have strong ties to Goldman Sachs (see: Hank Paulson), Obama will take heat because he is the Goldman Sachs crony in power. Fox News has already begun their drumbeat, but Obama’s ties to Goldman are simply too strong for more mainstream outlets to ignore. How will Obama deal with the political liability of being Goldman’s favorite politician, and hold on to the support of voters? Yesterday, he chose to ignore it, but this strategy will almost certainly backfire as the scandal grows and the media begins linking Obama with Goldman. But Obama does have options for addressing these issues. He is not a former Goldman Sachs executive, and he has never worked on Wall Street. He has a significant opportunity to distance himself from Wall Street’s culture of fraud by turning his back on his big-dollar Wall Street donors, and embracing the support of his small-dollar ones. By making a firm pledge to reject all future donations from individuals associated with the big banks and hedge funds, he can credibly demonstrate his political independence to the American people. Of course, as long as he continues to invite Goldman Sachs to join him — on his campaigns, at his speeches, in the White House — the fight against Wall Street’s fraud is a fight against the Obama administration.

Read the full article →

Video: Blanchflower Says Greece Delay May Spur ‘Other Dominoes’: Video

April 23, 2010

April 23 (Bloomberg) — Former Bank of England policy maker David Blanchflower, an economics professor at Dartmouth College and Bloomberg columnist, talks with Bloomberg’s Deirdre Bolton about the European Union’s delay in implementing its aid package to Greece and the impact on market sentiment. Blanchflower also discusses the results of his study on the correlation between money and happiness and the narrowing gap between genders in the U.S. when it comes to overall life satisfaction. (Source: Bloomberg)

Read the full article →

College Tanning Addicts Drink More Alcohol, Smoke More Pot, Study Finds

April 19, 2010

By Tom Randall April 19 (Bloomberg) — About one-third of college students who tried indoor tanning facilities were addicted to the artificial rays, and the addicts drank more alcohol and smoked more marijuana than other students, researchers found. The compulsive tanners met psychological criteria for addiction gauged by two different measurers, according to the study published today by the medical journal, Archives of Dermatology . About 42 percent of tanning addicts reported using more than one drug in the previous month, twice the rate of casual tanners. Indoor tanning can cause skin cancer, premature skin aging and eye damage, according to the U.S. Food and Drug Administration . The health overhaul signed by President Barack Obama last month will charge customers a 10 percent tax effective in July. Curbing the habits of sun-starved undergraduates may prove more difficult than previously thought, researchers wrote in today’s study. “Results suggest that treating an underlying mood disorder may be a necessary step in reducing cancer risk among those who frequently tan indoors,” wrote the researchers from Memorial Sloan-Kettering Cancer Center in New York and the State University of New York, Albany. “Individuals who use drugs may be more likely to develop dependence on indoor tanning because of a similar addictive process.” The study evaluated 421 college students in 2006. The students answered surveys designed to evaluate drug addiction. The surveys were modified to measure tanning addiction. Questions included: “Do you ever feel guilty that you are using tanning beds or booths too much?” and “Do you try other non-tanning-related activities but find you really still like spending time in tanning beds or booths best of all?” To contact the reporter on this story: Tom Randall in New York at trandall6@bloomberg.net .

Read the full article →